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Abstract
Herpes simplex viruses (HSVs), are among the most virulent and widespread pathogens;
they affect 60–90% of the population worldwide. Substantial evidence indicates a
possible association between pathogens and chronic disease. HSVs, among other viruses,
have been associated with increased risk for inflammatory diseases. However, prior
findings have been inconsistent on the role of infection in triggering autoimmune
response and chronic disease. This study builds on the premise that pathogens can induce
an inflammatory response and increase the risk for disease development. A representative
U.S. sample from NHANES, a national population-based cross-sectional survey, was
used to examine the relationship between HSVs infection and type 2 diabetes mellitus
(T2DM) and cardiovascular disease (CVD). Results from the two-tailed, Pearson chisquare test and multiple logistic regression analyses found no significant association
between HSV or multiple herpes virus infections and T2DM or CVD, which suggest
rather a secondary phenomenon. However, all the risk factors examined in this study
indicated an association with either T2DM, CVD or both. Two inflammatory markers, Creactive protein (CRP) and serum ferritin, were significantly associated with T2DM and
CVD. These findings have potential implications for social change as they support the
premise that high levels of CRP and ferritin may be associated with T2DM and CVD.
Existing guidelines for primary and secondary prevention of T2DM and CVD could be
expanded (a) to include CRP and ferritin as part of the health assessment for T2DM and
CVD in high-risk populations, and (b) to explore the effectiveness of CRP and ferritin as
predictive biomarkers and prognostic tools for T2DM and CVD.
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Chapter 1: Introduction to the Study
Background
The growing list of chronic diseases previously considered to have a
noninfectious etiology is of great public health concern (SoRelle, 1998). Cancer, for
example, one of the most studied chronic diseases, is also recognized as an inflammatory
disease that has been linked to an infectious etiology (Schlipköter & Flahault, 2010; Zur
Hausen, 2009). One of the mechanisms linked to the comorbidity of pathogens and
inflammatory diseases is that infection must be chronically active (Sfriso et al., 2010).
This pathogenic mechanism has been observed in infectious agents such as epstein-barr
virus (EBV), Helicobacter pylori (H. pylori), and herpes simplex viruses (HSVs), which
are able to elude immune recognition and HSVs can stay dormant and reactivate for the
life of the host (Kusters, van Vliet, & Kuipers, 2006; Lima et al., 2008). Of significant
note is the fact that infections may be cofactors that indirectly affect genetic mutations,
while the direct pathway to disease development may be noninfectious (Christen, Hagen,
Shigenaga, & Ames, 1999). This phenomenon can be explained by the fact that a
substantial part of the inflammatory disease processes may result from an autoimmune
response to chronic inflammation leading to the belief that the etiology of the disease is
not related to infection (Christen et al., 1999; Sfriso et al., 2010). Considerable evidence
has been accumulated in favor of chronic viral or bacterial infections with cardiovascular
diseases, diabetes mellitus, atherosclerosis, and Alzheimer’s disease, among other
chronic diseases (O’Connor, Taylor, & Hughes, 2006).
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Introduction
Researchers are beginning to understand the role that chronic inflammation may
play in the pathogenesis of chronic diseases (Lutsey, Pankow, Bertoni, Szklo, & Folsom,
2009). It has been documented that highly virulent agents may induce inflammation as a
result of a robust immune response creating a susceptible environment conducive to
disease development (Conrady, Drevets, & Carr, 2011; Lutsey et al., 2009; van der Kleij
& Yazdanbakhsh, 2003). The biological plausibility of theories linking pathogen-induced
inflammation and autoimmune-inflammatory disease has been examined in prior work
(Watts, Crimmins, & Gatz, 2008). Although promising findings have been reported, most
results have been inconsistent (Bauer & Meyer, 2011; Gómez, Laurés, Baltar, Melón,
Dıé z, & de Oña, 2005; Lutsey et al., 2009; Sethi et al., 2008; Sun et al., 2004).
Over the years, the epidemiology of the highly pathogenic HSVs has changed
dramatically. Eight out of the 80 known viruses in the herpes family to date are
recognized as human pathogens (Fatahzadeh & Schwartz, 2007). In the United States,
trends in genital herpes with HSV type 2 (HSV-2) showed a decrease of 21.0% (95% CI:
19.1-23.1) from 1988-1994 to 17.0% (95% CI; 15.8-18.3) from 1999-2004 among
individuals aged 14-49 years (CDC, 2010a, 2010b). Nevertheless, an increase among
individuals diagnosed with genital herpes with herpes simplex virus type 1 (HSV-1) has
been observed in later years, 1.8% in 1999-2004 versus 0.4% in 1988-1994 (P<.001)
(Malkin, 2004; Xu et al., 2006; CDC, 2010a, 2010b). This new trend in genital herpes
suggests a possible genetic crosstalk or immune-synergy between HSV-1 and HSV-2
infections (Chentoufi et al., 2012; Kimberlin, 2004; Kriebs, 2008; Mark et al., 2008).
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Worldwide, the prevalence of HSV is approximately 90% (Malkin, 2004; Smith
& Robinson, 2002; Wald & Corey, 2007). In the United States, over 50% of the
population is seropositive to HSV1 by the time they reach age 40 and approximately 25%
is seropositive to HSV2 (CDC, 2010b; Kimberlin, 2004; Xu et al., 2006). This is of great
public health concern given the evidence that people infected with HSV2 are up to three
times more likely to acquire HIV and to transmit the HIV virus to others compared to
people who are seronegative to HSV-2 and the new synergy trend observed between
HSVs and HIV (Chentoufi, 2012; Freeman et al., 2006; Holmberg et al., 1988;
McClelland et al., 2002; Schacker et al., 1998). According to the Centers for Disease
Control and Prevention (CDC, 2006), transmission risks of HSV-2 are higher since over
80% of those infected with the virus are asymptomatic, and the effectiveness of current
prevention measures for HSV-1 and HSV-2 is limited to the use of condoms and
prophylactic medications (Leone, 2005; Mell, 2008; Wald et al., 2001) and a potential
vaccine still in development (Belshe, 2012; Samandary, 2014). Additionally, the cost of
HSV-2 in the U.S. is expected to be nearly $2 billion by the end of 2015 (Szucs, Berger,
Fisman, & Harbarth, 2001). To better understand disease risks and to develop effective
treatments and prevention strategies, it is imperative to understand the epiphenomenon of
infectious agents and their possible correlation with common chronic diseases. Findings
from the present study inform the fields of medicine and public health about potential
prevention measures for individuals at risk of CVD and/or T2DM, who are also
seropositive to herpes virus infection.
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Statement of the Problem
HSVs are among the most virulent and widespread pathogens; they affect 60-90%
of the population worldwide (CDC, 2010; Smith & Robinson, 2002; Wald & Corey,
2007; Xu et al., 2006). Considering that HSVs have the ability to reactivate during the
lifetime of the host, it is possible that the recurrent autoimmune and inflammatory
response induced by these viruses may increase the risk for developing inflammatory
chronic diseases, including two of the top 10 leading causes of death in the United States:
T2DM and CVD (Lloyd-Jones et al., 2010; Lutsey et al., 2009). Most association studies
conducted with pathogens and chronic diseases have used small samples of specific
populations, including immunocompromised individuals, in clinical settings leading to
conflicting results (Rupprecht et al., 2001; Sun et al., 2004). As a result, there is minimal
understanding about the intricate relationship between infectious agents and chronic
diseases. In this study, I further examined the relationship between human pathogenic
HSVs and two chronic diseases, T2DM and CVD.
Purpose of the Study
This study sought to examine the potential relationship between HSV and two
chronic diseases, T2DM and CVD in a U.S. representative sample, aged 20-49. Although
inferences about causal factors cannot be made with cross-sectional studies, this study
was expected to contribute to the existing literature by providing additional evidence on
possible association between pathogens and chronic disease. I also examined if a higher
burden of pathogens, such as having more than one type of herpes virus—for example,
HSV-1, HSV-2, and cytomegalovirus (CMV)—increases the risk for developing T2DM
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and/or CVD or if it is merely a secondary phenomenon. Further, I evaluated the
relationship between three well-known inflammatory markers (CRP, serum ferritin, and
homocysteine) and T2DM and CVD. Lastly, the prevalence of reported HSV infection,
T2DM, CVD and selected inflammatory markers were examined to account for a true
representative sample.
Research Questions
The following hypotheses derived from the literature and steered the present
study:
H11: Is HSV-1 infection associated with higher risk of developing T2DM?
H01: HSV-1 infection is not associated with higher risk for T2DM.
H12: Is HSV-2 infection associated with higher risk for of developing T2DM?
H02: HSV-2 infection is not associated with higher risk for T2DM.
H13: Is HSV-1 infection associated with higher risk of developing CVD?
H03: HSV-1 infection is not associated with higher risk for CVD.
H14: Is HSV-2 infection associated with higher risk of developing CVD?
H04: HSV-2 infection is not associated with higher risk for CVD.
H15: Is having a higher burden of pathogens (HSV-1 + HSV-2+CMV) associated
with a higher risk of developing T2DM and/or CVD?
H05: A higher burden of pathogens is not associated with higher risk for T2DM
and/or CVD.
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The study methodology including study design, dependent and independent
variables, covariates and potential confounders will be discussed in detail in Chapter 3,
Methodology.
Definition of Terms
Acute-phase response (APR): The initial response or acute inflammation response
of the innate immune system to injurious stimuli caused by harmful agents (Gruys,
Toussaint, Niewold, & Koopmans, 2005).
Autoimmune-inflammatory response: A mechanism induced by the innate immune
system when tissues are injured by pathogens, trauma, toxins, extreme heat and cold, to
name few. Damaged cells release chemicals that in turn cause cells to leak fluid to tissues
causing swelling; hence inflammation (Firestein, 2011).
Cardiovascular or heart disease (CVD): According to the World Health
Organization (WHO), CVD refers to a variety of disorders of the heart, to include:
Coronary heart disease (CHD), which is also known as coronary artery disease (CAD).
CHD is caused by the build-up of plaque on the wall of the heart arteries blocking the
blood and oxygen supply to the heart. Angina or chest pain is one of the most common
risk factors for heart disease. Heart attack also known as myocardial infarction (MI) is
caused by a blood clot, which in turn blocks the blood flow to the heart causing damage
to the heart (Bonow RO, Mann, Zipes, & Libby, 2011; Greenland et al., 2012; WHO,
2012).
Type 2 diabetes mellitus: Characterized by an array of metabolic dysfunctions
including insulin resistance and inadequate insulin and glucagon secretion. In this study,
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the American Diabetes Association (ADA) criteria were utilized for the diagnosis of
T2DM. According to Mahler and Adler (1999) “Impaired fasting glucose was defined as
fasting plasma glucose of 110 or more and 125 mg/dl or less. Impaired glucose tolerance
(IGT) was defined as a 2-h plasma glucose value of 140 or more and of less than 200
mg/dl during an oral glucose tolerance” (p. 1165). Hemoglobin A1C measurements were
applied to the diagnoses of diabetes (6.5% or greater) and (5.7%-6.4%) for prediabetes
(ADA, 2003; Mahler & Adler, 1999).
Inflammatory markers: Also known as biomarkers are useful clinical diagnostic
and prognostic tools for ruling out specific conditions. For example, elevated levels of C reactive protein (CRP), a protein synthesized by the liver, are an indication of
inflammation present in the body. As a result, CRP is used as a biomarker for the risk of
CVD and T2DM. Interleukin or IL-6, a protein-coding gene, functions with inflammation
in response to harmful stimuli such as infection. Fibrinogen, a protein synthesized by the
liver, helps to stop clots from forming by converting thrombin into fibrin and may
indicate a risk for diabetes. Elevated levels of ferritin, a protein that controls the levels of
iron in the blood, may be an indication of inflammation, heart failure, diabetes and other
conditions. Elevated levels of homocysteine, an amino acid found in the blood plasma,
increase the risk for heart disease (Ballantyne & Nambi, 2005; Davidson, 2011; Ridker,
Hennekens, Buring, & Rifai, 2000; Watson, Round, & Hamilton, 2012).
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Significance of the Study
Social Change Implications
Results from this study are expected to add to the growing body of evidence that
links infectious agents with chronic disease. A positive association between HSV and
T2DM and CVD would provide the medical community and the public health field with
valuable information that can be translated into clinical practice. Serologic testing for
HSV could be included as part of a routine health assessment for patients at high risk for
T2DM and CVD. Preventive screening could improve the health of susceptible groups,
reduce health care cost, and foster policy change. Additionally, existing prevention
guidelines for T2DM and CVD could be expanded to include inflammatory biomarkers—
including CRP, serum ferritin, and homocysteine—as predictive biomarkers for T2DM
and CVD (Oshaug, Bugge, Bjonnes, Borch-Iohnsen, & Neslein, 1995; Braly, & Holford,
2003; Laakso, 2008; Watson et al., 2012). This study could support more collaborative
research across disease entities—such as T2DM, CVD and HSV—which are traditionally
housed in separate silos for research and funding.
Assumptions, Limitations and Strengths
This study assumed that the survey participants were randomly selected and thus
there was little or no selection bias. It is also assumed that the survey instrument used to
collect the NHANES data was appropriate to measure the selected variables to test the
research questions of this study. The clinical, physical, and self-reported data collected
through NHANES annually provides a comprehensive health profile of each survey
participant and allows for data validation.
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The present study has a few limitations. First, it uses a cross-sectional design,
which limits any causal inferences that can be made between associated variables.
Second, it evaluates only a select number of inflammatory biomarkers based on those
included in the NHANES dataset, rather than a more comprehensive list from a literature
review. Third, it is not possible to determine whether the HSV infection included in the
analysis is primary or recurring infection with the NHANES data. As a result, inferences
cannot be made on truly primary infections versus recurring ones. This limitation also
restricts the ability to determine whether any association exists between the chronicity of
an HSV infection and the outcomes of interest, T2DM and CVD. Fourth, data to examine
the interrelationship between inflammation, HSV and T2DM and/or CVD was not readily
available. Fifth, a number of selected independent variables were collected through selfreport, which may result in an inaccurate or biased recall.
This study also has several strengths. First, it uses a representative sample from a
national population-based survey; hence, conclusions and implications drawn from this
study can be applied to the general population. Second, the study uses serological
measures for detecting antibodies for HSV-1 and HSV-2, as well as standard indicators
for diabetes, CVD and inflammation markers, which allow for drawing conclusions from
positive cases. Potential cofounders for T2DM and CVD seem unlikely given that most
traditional factors (such as age, gender, smoking, and socioeconomic status) and
nontraditional markers (such as C-reactive protein levels) were weighted and controlled
for in the study population.
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Summary
This is the first study to offer a closer look at the possible association of HSV and
two leading chronic diseases, T2DM and CVD, using a nationally representative sample.
The study design supports the examination of the cross-sectional relationship between
seropositivity of HSV and these two inflammation-prone diseases. Although causal
conclusions cannot be made with this cross-sectional study, findings and implications
could provide the scientific community with additional evidence on whether a possible
association between HSV and T2DM and/or CVD exists. This study is also the first to
examine the association between three inflammatory biomarkers and T2DM and CVD, in
addition to evaluate the burden of infection among individuals with T2DM or CVD. An
overview of each of the independent and dependent variables, study methodology,
discussion of study results, and recommendations are discussed in the next chapter.
Chapter 2 begins with a review of the existing literature on the suggested
association between infectious diseases and inflammatory response. The chapter includes
a description of the pathogenic effect in autoimmune-inflammatory response theory,
which serves as the theoretical framework for the current study and provides substance
regarding the possible association of innate immunity, inflammation, and pathogeninduced acute response. The chapter also discusses the possible mechanisms involved in
the activation of innate immunity of T2DM and CVD. Further, the epidemiology,
pathogenesis, and immunopathological aspects of herpes virus infection—as well as the
role of inflammation in the pathogenesis of T2DM and CVD—are examined. The chapter
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concludes with association studies between HSV and T2DM and/or CVD and research
gaps.
Chapter 3 describes the study’s methodology, including the analysis conducted to
answer the research questions, including the use of regression analyses (chi-square,
logistic, and stepwise) as a valid means to measure the possible relationship between
HSV and T2DM and/or CVD. In addition, Chapter 3 includes a description of the study
design, study population, variables to be studied, potential bias, and ethical
considerations.
Chapter 4 offers a summary of the analyses and the results. It describes the
demographic and health characteristics of the study population as well as the distribution
of the herpes viruses, biomarkers, diabetes and cardiovascular disease in the study
sample. The prevalence of T2DM and CVD among individuals with HSV and selected
covariates as well as the potential relationship between these are examined. Results are
illustrated in tables and figures.
Chapter 5 provides an overview of the findings, the conclusion, and the
implications for social change. This chapter also evaluates potential reasons for study’s
findings and existing evidence in support of them. Since a national representative sample
was used in this study, association inferences would be appropriate. Limitations of the
present study are also discussed.
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Chapter 2: Literature Review
Introduction
A comprehensive review of the literature relevant to this study was conducted.
Two electronic databases were searched: Medline and PubMed. Google Scholar and
references cited in key articles were also evaluated. Search terms were selected from the
literature review from peer-reviewed journals dating back 1970: herpes (inflamed,
inflammation or inflammatory) and (disease or diseases or illness), herpes or HSV and
(cardiovascular disease or CHD or CVD) and (diabetes, type 2 diabetes mellitus, T2DM)
and (inflammation or inflammatory) and (disease or diseases), herpes or HSV and (CHD
or CVD) and (inflammation or inflammatory) and (disease or diseases), and T2DM and
CVD inflammatory markers. Peer-reviewed articles and/or abstracts in English were
retrieved. This chapter provides (a) an overview of the theoretical constructs; (b) the
epiphenomena of the autoimmune-inflammatory response, HSV, CHD, and T2DM; (c)
the possible interaction among these constructs; and (d) the different mechanisms that
could account for an association.
Theoretical Constructs
This study builds on the premise that pathogens, particularly those that can
reactivate during the lifetime of the host, can induce an autoimmune-inflammatory
response. Chronic, inflammation-prone diseases may thereby increase (Conrady et al.,
2011; De Tiege, Rozenberg, & Heron, 2008; Itzhaki & Wozniak, 2008; McKie, Brown,
MacLean, & Graham, 1998). Although there is a great deal of knowledge about the
antigen-antibody (immune) mechanism produced by B and T lymphocytes and the
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inflammatory cytokines, such as interferon- , interleukin-6 and chemokines (Figure 1),
the pathogenic effect in autoimmune-inflammatory response is not well understood.
Limited research has been conducted with human subjects and animal models to examine
the interaction between infectious agents such as herpes viruses and the immune system
and their effect on inflammation and potentially disease development, making it difficult
to apply the theory to clinical medicine (Moynihan & Ader, 1996).

Figure 1. Nature and functions of auto-antibodies (A-inflammatory cytokines and
chemokines & B-antibody & antigen response). From “Nature and Functions of
Autoantibodies,” by K. Elkon and P. Casali, 2008, Nature Clinical Practice
Rheumatology, 4, p.12. doi: 10.1038/ncprheum0895 Adapted with permission of the
author.
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Innate Immunity, Inflammation, and Acute-Phase Response
Research studies on one of the most studied human herpes virus, HSV type 5
(HHV-5), also known as cytomegalovirus (CMV) indicate that this specific virus strand
may be dependent on immune activation as it has been observed in tissues targeted by the
immune system (Stevens, 1989; Steiner,1995). The ability of this virus to control
immunological functions by activating T cells, a type of white blood cell that plays an
important role in the immune system, and to produce cytokines for the virus to reactivate
from its latent phase in macrophages suggests that it may play a causative role in the
development of cancer, CVD, and autoimmune diseases (Soderberg-Naucler, 2006).
Soderberg-Naucler (2006) illustrated how CMV may utilize inflammation as a
mechanism to reactivate itself, then spread to other cells in the inflamed tissue, and
through its ability to affect numerous cellular and immunological functions, activates the
innate immunity causing disease (Figure 2). A similar mechanism was observed by
Pickup (2004) in examining the role of inflammation and the activation of the immune
system in the pathogenesis of T2DM. This epiphenomenon has been observed in
inflammatory diseases such as multiple sclerosis, diabetes, and cancer (Pickup & Crook,
1998; Soderberg-Naucler, 2006). Additionally, these diseases may provide a
microenvironment that may in turn reactivate the virus triggering and sustaining
inflammation (Soderberg-Naucler, 2006). While the innate immune system is the body's
main defense against external threats such as infections, inflammation also functions as
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the local protective response to tissue injury, which acute-phase reactant proteins such as
CRP, cytokines IL-6, and TNf-alpha assist with limiting injury and healing tissue (Cone,
2001; Gabay & Kushner, 1999; Muller et al., 2002). An increase in these and other acutephase responses induced by inflammatory cytokines when having fever or lethargy, have
been observed in diabetes, atherosclerosis, arthritis and cancer patients (Pickup, 2004;
Soderberg-Naucler, 2006).
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Figure 2. Mechanism between inflammation, infection and immunological functions.
From “Does Cytomegalovirus Play a Causative Role in the Development of Various
Inflammatory Diseases and Cancer?” by C. Soderberg-Naucler, 2006, Journal of Internal
Medicine, 259(3), p. 223. doi:10.1111/j.1365-2796.2006.01618.x. Adapted with
permission from John Pick Up. Adapted with permission of the author.
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Relationship Between Pathogens and Inflammatory Diseases
The association between human diseases and infectious agents has been widely
documented. Alzheimer’s disease, for example, has been associated with various
pathogens including HSV-1, Chlamydia pneumoniae, and Helicobacter pylori (Karim,
2014; Kountouras et al., 2009; Shima, Kuhlenbaumer, & Rupp, 2010). HSV-1 has been
linked to Alzheimer’s patients who have the APOE-4 form of APOE gene, which enables
HSV-1 to enter into the brain cells (Itzhaki et al., 2008). Atherosclerosis, CHD and
Asthma, particularly adult-onset asthma has been associated with Chlamydia pneumoniae
and HSV-1, and the latter with rhinovirus (Gern, 2009; Hahn, Dodge, & Golubjatnikov,
1991; Prager et al., 2002; Roivainen et al., 2000). Further, approximately 20% of all
cancers have been linked to pathogenic agents (Pisani, Parkin, Munoz, & Ferlay, 1997).
Human papillomaviruses (HPV) have been associated with several type of cancers,
including anal and colorectal cancer, breast cancer, cervical cancer, lung cancer, and
some skin carcinomas (Abramowitz et al., 2010; Bosch, Lorincz, Munoz, Meijer, &
Shah, 2002; Burnett-Hartman, Newcomb, & Potter, 2008; Joh et al., 2010; Lawson,
Gunzburg, & Whitaker, 2006).
Similar to HSV-1, CMV or HHV-5, is often acquired during childhood, and
affects the majority (over 70%) of the world’s population (Britt & Mach, 1996; Onorato,
Morens, Martone, & Stansfield, 1985). As with most herpes viruses, CMV can spread
through bodily fluids including saliva, breast milk, semen, blood and tissue transplants
(Britt et al., 1996). Once acquired, CMV can persist and live as a latent infection in the
host (Onorato et al., 1985). In a study conducted by Soderberg-Naucler and colleagues
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(2006), a high prevalence of CMV was found in most of the HIV-infected patients who
received organ or bone marrow transplants. CMV has also been associated with longterm complications such as atherosclerosis, restenosis, transplant vascular sclerosis
(TVS), rheumatoid arthritis, and systemic lupus erythematosus or SLE (Grattan et al.,
1989; Torok-Storb, Fries, Stachel, & Khaira, 1993; Zhou et al., 1996). CMV has also
been associated with several cancers, dementia, lupus, metabolic syndrome, myocardial
infarction, and lately it has been associated with T2DM (Barzilai et al., 2007;
Dziurzynski et al., 2012; Gabrylewicz et al., 2003; Nabipour, Vahdat, Jafari, Pazoki, &
Sanjdideh, 2006; Rider, Ollier, Lock, Brookes, & Pamphilon, 1997; Roberts & Cech,
2005a). Moreover, CMV is one of the most common birth defect causing infections
influencing mental retardation and hearing loss (Fowler et al., 1992; Onorato et al.,
1985).
Chen and colleagues (2012) examined the prevalence of CMV among older adults
and showed that seropositive cases of CMV were also T2DM positive (17.2% vs 7.9%,
(p = 0.016) with significant high levels of HbA1c (p = 0.014). These findings give basis
to suggest that CMV and T2DM may be linked by the autoimmune inflammatory
response, which may increase susceptibility to the virus or alternatively increase the risk
of disease development (Jun & Yoon, 2003). This also may be an indication that
inflammation may act as a mediator in disease development leading to believe that there
is no link to pathogenic etiology when in fact there may be (Jun & Yoon, 2003; Lecube et
al., 2004 Mehta et al., 2003; Roivainen et al., 2000; Zhu et al., 2001). The link between
infectious diseases and T2DM, CVD, coronary artery disease (CAD) and atherosclerosis,
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however, has been controversial given that the cause of most of these conditions are
considered multifactorial (Jun et al., 2003; Luscher, Creager, Beckman, & Cosentino,
2003; Zhu et al, 2001). Hypertension, obesity, smoking, hypercholesterolemia, and
genetic predisposition are some of the common risk factors associated with most of these
conditions (Fong, 2000; Ross, 1999). Obesity, for example, is known to play an important
role in insulin resistance, diabetes and atherosclerosis (Fernandez-Real, Ferri, Vendrell,
& Ricart, 2007; Karjala et al., 2011). Nevertheless, studies conducted with CAD patients
showed no association with none of the traditional risk factors while their atherosclerosis
appeared to have started in early childhood (Nieto, 1998; Ridker, 1999). These results
support the premise that atherosclerosis may have a pathogenic etiology and chronic
inflammation may be a precedent mechanism in the development of the disease. Further
examination conducted by Fong (2000) showed epidemiological, pathological, and
biological evidence supporting the association between CVD and infectious agents
including Chlamydia pneumoniae, cytomegalovirus (CMV), HSV, and Helicobacter
pylori (H. pylori). However, some of the association between CMV and CVD were found
to be weak and in some studies controversial (Fong, 2000). The link between Chlamydia
pneumonia (C. pneumonia) and CVD, however, seems to be well established
(Ossewaarde, Feskens, De Vries, Vallinga, & Kromhout, 1998). The ability of infectious
agents to induce inflammatory mechanisms and immune response has been widely
demonstrated experimentally (Muhlestein, & Anderson, 2003).
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Inflammation and Activation of Innate Immunity in Type 2 Diabetes
There is a great deal of evidence that suggests inflammation is involved in the
pathogenesis of T2DM (Navarro & Mora, 2005; Pickup & Crook, 1998; Schmidt et al.,
1999; Temelkova-Kurkschiev et al., 2002). Yet, the role of innate immunity and
inflammation in the development of the disease is still uncertain (Saito et al., 2000;
Schmidt et al., 1999; Snijder et al., 2003; Spranger et al., 2003). Given that the innate
immune system is the body's main defense against external threats including infections,
activation of innate immunity may explain some of the different clinical and biochemical
conditions in T2DM patients (Fearon, 1997). These include obesity, hypertension,
accelerated atherosclerosis, dyslipidemia, and limb ischemia. Inflammatory markers such
CRP and interleukin-6 as well as traditional risk factors used to predict T2DM and CVD
such as age, inactivity, nutrition, smoking, stress, and low-birth weight have also been
identified as innate immunity activators (Freeman et al., 2002; Pradhan, Manson, Rifai,
Buring, & Ridker, 2001). Pradhan and colleagues (2001) prospective and nested casecontrol study aimed to determine the role of inflammatory markers interleukin and CRP
in the development of T2DM. One hundred eighty-eight women from a national sample
of 27,628 healthy middle-aged women participated in the clinical study and were
followed since 1992. Elevated levels of CRP and IL-6 were observed among those who
developed diagnosed T2DM over a 4-year follow-up period. Baseline levels of IL-6 and
CRP (P <.001) were significantly higher among women who developed T2DM than
among those nondiagnosed. The relative risks for developing T2DM among women with
high levels of these inflammatory markers were 7.5 for IL-6 (95% CI, 3.7-15.4) and 15.7
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for CRP (95% CI, 6.5-37.9). Associations persisted after adjustment for traditional risk
factors including fasting insulin levels, smoking, exercise, alcohol use, BMI, and family
history of diabetes. A cross-sectional study conducted by Gregor & Hotamisligil (2011)
with nondiabetic subjects and individuals with impaired glucose tolerance found a
positive correlation between plasma insulin concentration, triglycerides, body mass index
(BMI) and inflammation-induced acute-phase reactants. Elevated acute-phase markers
have also been observed in clinical studies conducted with diabetic patients in
comparison with nondiabetic subjects (Sriharan et al., 2002). Similar metabolic changes
were reported by Richardson & Tayek (2002) in T2DM patients with systemic injury
caused by trauma, infection, or cancer. These findings may imply that the injury response
may be a factor in insulin resistance or increase in glucose production TemelkovaKurktschiev, Henkel, Koehler, Karrei, & Hanefeld, 2002). Similarly, cytokine-induced
insulin resistance, may increase the acute-phase response increasing the risk for T2DM
and CVD (Fernandez-Real & Ricart, 1999). Concentrations of CRP, fibrinogen, and
plasminogen activator inhibitor-1 (PAI-1) were studied with 1,047 nondiabetic subjects
enrolled in a longitudinal Insulin Resistance Atherosclerosis Study (Festa, D'Agostino,
Tracy, & Haffner, 2002). Results from this study indicated significant increased levels of
these inflammatory markers among T2DM cases than among no converters also known
as controls (fibrinogen p = 0.013; CRP = 0.0001; PAI-1 p = 0.0001). PAI-1 was found to
be an independent risk factor for T2DM.
In his work, Pickup (2004), demonstrates the interaction between the different
mechanisms and factors known to be activators of the innate immune system interacting
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with cytokine production, which might leads to insulin resistance and other components
of the metabolic syndrome (Figure 3). This mechanism is of particular interest since
activated innate immunity might be a possible common antecedent of both T2DM and
atherosclerosis (Pickup & Mattock, 2003). Another mechanism examined by Pickup
(2004) is the fetal and neonatal programming, which suggests that prolonged
environmental stressors may cause genetic mutations which may alter normal
physiological responses to stress and other environmental exposures causing disease in
individuals with a higher propensity to a hyper-responsive innate immune system. This
theory is supported by the premise that low birth weight has been linked to high levels of
acute-phase reactants in adults (Barker, 1995); therefore, it is assumed that acute-phase
reactants may be precursors to certain types of autoimmune-inflammatory disease
(Phillips et al., 2000).
Genetics and race have also been examined as possible mechanisms in the
development of T2DM. In a study conducted by Pannacciulli and colleagues (2002),
higher levels of CRP were recorded in women with family history of T2DM compared to
those without a family history. When looking at the effects of race in the acute-phase
response, higher concentrations of serum sialic acid have been reported in Asian diabetic
patients with Indian descendant compare to White diabetic subjects (Pickup, Chana,
Mattock, Samuel, & Mather, 1996). Another mechanism considered to influence the
development of T2DM is individual diet, which may contribute to the activation of the
innate immune system and chronic inflammation. Bakker et al. (2010) study
demonstrates that excess and repeated dietary intake of certain high fatty foods may
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affect the production of proinflammatory cytokines. In fact, prior studies conducted with
diabetic subjects have shown a relationship between elevated levels of CRP and acutephase reactants (TNF-alpha and IL-6) and obesity (Vlassara et al., 2002).
Further, several studies have linked a number of inflammatory makers with
specific ethnic groups and gender. In a study conducted with a middle-aged population
diagnosed with T2DM, Schmidt et al. (1999) found a series of markers including white
blood cell count, low serum albumin, fibrinogen, alpha 1-acid glycoprotein, and sialic
acid, which have also been used to predict CVD (Kannel, Wolf, Castelli, D’Agostino,
1987; Meade, 1997; Wannamethee et al., 2002; Yarnell et al., 1991). CRP has been
observed predominantly in the older Scottish (Freeman et al., 2002) and Japanese
population (Nakanishi, Yoshida, Matsuo, Suzuki, & Tatara, 2002) and German men
(Spranger et al., 2003; Thorand et al., 2003). Both, CRP and IL-6, have been found
mainly in women (Pradhan, Manson, Rifai, Buring, Ridker, 2001; Snijder et al., 2003)
whereas white blood cell count have been observed in Pima Indians (Vozarova et al.,
2002). CRP, fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) have been
associated with multiethnic subjects with insulin resistance and atherosclerosis (Barzilay
et al., 2001; Duncan et al., 2000; Festa, D'Agostino, Tracy, & Haffner, 2002).
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Figure 3. Activators of the innate immune system, insulin resistance, T2DM and
atherosclerosis. From “Inflammation and Activated Innate Immunity in the Pathogenesis
of Type 2 Diabetes” by J.C. Pickup, 2004, Diabetes Care, 27(3), p. 816.
doi:10.2337/diacare.27.3.81. Adapted with permission of the author.

Inflammation and Activation of Innate Immunity in Cardiovascular Disease
Inflammation has also been associated with the pathogenesis of atherosclerosis
(Blake & Ridker, 2002; Galkina & Klaus, 2009). Inflammatory markers previously
associated with T2DM including CRP, fibrinogen, TNF sialic acid, and cytokines have
also been found to increase the risk for myocardial infarction, stroke, peripheral vascular
disease, and CVD mortality (Libby, Ridker, & Maseri, 2002; Ridker, 1999). Most risk
factors such as hyperglycemia, dyslipidemia, and alterations in inflammatory mediators
closely related to insulin resistance have also been observed in patients with CVD
(Erdmann, 2005). Furthermore, it has been documented that serum sialic acid predicts
cardiovascular mortality in T2DM patients independently of atherosclerosis
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predisposition (Pickup et al., 1995). This findings suggests that innate immune response
is a common precedent in atherosclerosis and diabetes. Thus, the acute-phase responses
inherent to T2DM may promote the acceleration of atherosclerosis in diabetic patients
(Pickup & Mattock, 2003). However, inflammatory markers have been observed in
diabetic subjects without atherosclerosis and other vascular complications (Schmidt et al.,
1999). Yet, other manifestations and complications of T2DM including the presence of
infectious agents, might further enhance inflammatory response (Crook, Tutt, Simpson &
Pickup, 1993). Additional evidence indicates that diabetic patients with high incidence of
atherosclerosis suffer from impaired immune response to pathogens leading to a greater
risk for infection (Heymann et al., 2008). Epstain and colleagues (1999) studied patients
who were seropositive to CMV and found an odd ratio of 1.3 (p = 0.7) and elevated CRP
levels (odds ratio 2.3, p = 0.2) indicating a higher prevalence of CAD in patients who had
combined CMV and elevated CRP levels (odds ratio 4.3, p = 0.01). Findings also showed
a relation between infection, inflammation and CAD influenced by gender. In men, prior
CMV infection was not associated with CAD, but rather with high levels of CRP. In
women, the opposite effect was observed. Prior CMV infection was found to be
independently predictive of CAD (Epstein, 2002).
The relation between chronic inflammation and pathogen burden in relationship to
chronic diseases has also been examined. Lutsey and colleagues (2009) used a random
sample of 1,000 subjects, ages 45-84, from the Multi-Ethic Study of Atherosclerosis
(MESA) to determine the cross-sectional relationship of five pathogens including
C.pneumoniae, CMV, H. pylori, hepatitis A and HSV and T2DM. Results from this study
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showed a higher prevalence of diabetes among subjects with a pathogen burden greater
than three. No association was observed between individual infection agents and diabetes
status suggesting no etiology role of infectious pathogens and the development of
diabetes. However; a similar study was conducted with MESA to examine the association
of cardiovascular pathogen burden and immune response in relation to socioeconomic
and psychosocial gradients. Although the role of infection in CVD, particularly in
atherosclerosis remains elusive, this study showed increased rates of CVD among
subjects with a higher pathogen burden and low socioeconomic levels and chronic stress
(Aiello et al., 2009). These findings suggest that a high burden rather than a single
pathogen may be associated with increased risk of infection-related inflammation and
cardiovascular damage (Zhu et al., 1999; Zhu et al., 2001). Further, stress has been linked
to virus reactivation, which in turn flare up inflammation causing a dysfunctional
immune response and leading to cardiovascular disease (Binkley et al., 2013).
A literature review examining the pathogenic mechanisms between psoriasis and
CVD, particularly atherosclerosis, indicated that both diseases fused into inflammation
(Ghazizadeh, Shimizu, Tosa, & Ghazizadeh, 2010). When inflammation is induced, Tcells are activated, chemokine and cytokine cells are produced resulting in the formation
of psoriatic or atherosclerotic plaque. Similarly, a cross-sectional study conducted by the
Netherlands Institute for Health Sciences Research compared patients with inflammatory
arthritis (n = 1,518), patients with T2DM (n = 11,959), patients with osteoarthritis
(n=4,040) and controls (n = 158,439) to determine if there was an association between an
increased CVD burden on patients with selected inflammatory diseases. Study findings
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showed a significantly moderate to high prevalence of CVD in arthritis cases OR = 1.5
[1.2-1.9]) and T2DM cases OR = 1.3 [1.2-1.4] (Nielen et al., 2012). These findings
demonstrate that these conditions share common underlying mechanism, which also lead
to the assumption that inflammation might increase the risk for developing common
chronic inflammatory diseases.
Epidemiology of Herpes Viruses
Herpes simplex virus infections are prevalent worldwide (Malkin, 2004; Smith &
Robinson, 2002). HSV-1 is more common than HSV-2 (Bradley, Markowitz, Gibson,
McQuillan, 2014; Lafferty, 2002; Looker, Garnett, & Schmid, 2008). HSV-1 is acquired
in early childhood with prevalence rates up to 40% by five years of age and by adulthood,
HSV-1 affects over 60% of the population in the U.S. (Chayavichitsilp, Buckwalter,
Krakowski, & Friedlander, 2009; Kimberlin,2014: Liesegang, 2001; Xu et al., 2006).
Seroprevalence are similar worldwide; however, rates vary by country (kimberlin, 2014;
Malkin, 2004; Smith & Robinson, 2002). However, in the United States, about one in six
Americans (16.2 %) between the ages of 14 and 49 are infected with HSV-2. HSV-2
seroprevalence estimates are almost two times higher among women (20.9%) than in men
(11.5%); over three times higher among blacks (39.2%) than in whites (12.3%); with
African American women disproportionately affected (48%) (CDC, 2010b; Fanfair et al.,
2013; Johnson et al., 1989). In 2003, over 500 million people worldwide were estimated
to be infected with HSV-2, with the lowest prevalence rates in Europe and highest in
Africa (Looker et al., 2008).
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Pathogenesis of Herpes Viruses
Herpes viruses are among the top leading cause of viral disease in humans of
public health significance (Todar, 2009). These viruses have the ability to cause acute
disease or remain latent, and reactivate over and over during the lifetime of the host
(Roizman, Knipe, & Whiteley, 2007). HSV-1 and HSV-2 are responsible for causing
infections in the orofacial region, central nervous system, and the anogenital region
(Taylor, Brockman, McNamee, & Knipe, 2002). HVS-1 is spread through saliva of an
infected person, mainly through common cold sores and blisters, while HSV-2 is spread
mostly through sexual contact (Sacks et al., 2004; Taylor, Brockman, McNamee, &
Knipe, 2002). Both HSV species are ubiquitous and highly contagious regardless of
symptomology (Kesson, 2001).
The biology of herpes viruses is described by Holmes (1999) in his book, (3rd ed)
Sexually Transmitted Diseases. These viruses belong to the family of DNA enveloped
viruses known as Herpesviridae. Holmes (1999) explains that humans are natural
reservoirs for HSV, which could cause mild to severe conditions in humans including
encephalitis and meningitis. Conversely, the viral membrane of these viruses is sensitive
to an array of chemicals and substances and would not survive in harmful environmental
conditions (Hunt, 2010). In fact, a cell with a damaged lipid envelop is not be infectious
and transmission from cell to cell is necessary for the virus to survive (Hunt, 2010).
Nevertheless, these viruses have the ability to bind to the cell surface; fuse into the cell
membrane and the inner nucleus where DNA replication occurs; encode viral proteins
and synthesize viral DNA genome to replicate itself (Mingo, Han, Newcomb, & Brown,
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2012; Shimomura, 2008). If the virus cannot synthesize viral proteins and enzymes in
host cells or the host cells do not allow such replication due to the cell’s own
composition, the virus would not be able to replicate (Mingo et al., 2012). Yet, herpes
viruses are ubiquitous opportunistic pathogens. They have the ability to infect
lymphocytes or epithelial mucosal cells; travel to and stay latent in nucleated neuron; and
continue to reactivate at the same site of the initial infection (Mingo et al., 2012).
Latency, which means that the virus remains dormant in the nerve cells, also plays
an important role in the survival of HSV and host immune suppression (Steiner, 1995).
Most adults carry HSV in its latent’s phase (Steiner, 1995). Once the virus cells are
present in the body, antibodies are released, and T cells and macrophages are activated to
kill infected cells (Khanna, Bonneau, Kinchington, & Hendricks, 2003). Given that HSV
can infect almost any human cell, cell-mediated immunity for suppressing the infection is
of great importance (Khanna et al., 2003). This immune response is normally followed by
an inflammatory response that leads to some disease symptoms (Huang, Xie, Xu, Li, &
Zao, 2011). Other known factors that might trigger a recurrence of the viral infection and
may contribute to disease symptoms include stress, exposure to sunlight, heat, among
others (Huang et al., 2011).
On rare occasions, herpes infections can result in serious sequelae and even lifethreatening complications including meningitis and encephalitis and other opportunistic
infections such as keratitis and gingivostomatitis, particularly in neonates (Stanberry et
al., 2000; Stanberry, & Rosenthal, 2002). Recent findings also suggest that HSV may
increase the risk for diseases such as HIV/AIDS, cervical cancer, cardiovascular disease,
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and metabolic syndrome (de Martel & Franceschi, 2009; Nabipour et al, 2006; Roivainen
et al., 2000; Zhu et al., 2009). As described by Hunt (2010), Sandri-Goldin (2006), and
Whitley (1996), there are eight herpes viruses known to be pathogenic to humans (Table
1). These include Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2),
Varicella zoster virus (VZV) or HHV-3, Epstein-Barr virus (EBV) or HHV-4,
Cytomegalovirus (CMV) or HHV-5, Roseolovirus also known as Herpes Lymphoytopic
virus or HHV-6, Roseolovirus or HHV-7, and Kaposi’s Sarcoma-associated herpes virus
or HHV-8.
Table 1
Herpes Viruses Known to be Pathogenic to Humans
Virus

Common Name

Subfamily

Human herpes virus 1

Herpes Simplex type 1

alpha

Human herpes virus 2

Herpes Simplex type 2

alpha

Human herpes virus 3

Varicella zoster

alpha

Human herpes virus 4

Epstein-Barr

gamma

Human herpes virus 5

Cytomegalovirus

beta

Human herpes virus 6/7 Exanthum subitum roseola infantum beta
Human herpes virus 8

Kaposi’s Sarcoma

gamma

Similar to HSV-1 and HSV-2, VZV or HHV-3 virus targets primary
mucoepithelial cells, stay dormant for the life of the host in the neuron cells, and spread
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through close and sexual contact with an infected person (Table 2). VZV is responsible
for causing chickenpox and shingles and is considered airborne. HHV-4 targets B cells
and epithelial cells, remains latent in B cells, and is spread through close contact,
transplants and transfusions as well as vertical transmission (from mother to infant).
Pathogenesis of this virus includes mononucleosis, Burkitt’s lymphoma and other
lymphoma-like clinical symptoms associated with persons living with AIDS. HHV-5
targets and stays dormant in monocyte, lymphocyte, and epithelial cells. It manifests as a
mononucleosis-like syndrome and spreads through contact with saliva. HHV-6 and
HHV-7 target and stay dormant primary in T cells. It has been suggested that these
viruses may spread through close contact and air. Both viruses cause roseola infantum
which is also known as the sixth disease that causes rashes in infants and young kids.
HHV-8 targets primary lymphocyte cells and stays dormant in B cells. This type of virus
causes Kaposi’s sarcoma and Multicentric Castleman’s Disease. The virus spreads
through close and sexual contact with the infected person (Hunt, 2010; Sandri-Goldin,
2006; Whitley, 1996).
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Table 2
Properties of Herpes Viruses
Human
Name
Herpes
Type
1
Herpes simplex1 (HSV-1)
2
Herpes simplex2 (HSV-2)
3
Varicella Zoster
virus (VSV)

Subfamily

Alphaherpesvirinae
Alphaherpesvirinae
Alphaherpesvirinae

Target cell type

Latency

Transmission

Mucoepithelia

Neuron

Close contact

Mucoepithelia

Neuron

Mucoepithelia

Neuron

Close contact
usually sexual
Contact or
respiratory
route

B lymphocytes

Saliva

4

Epstein-Barr
Virus (EBV)

5

Cytomegalovirus Betaherpes(CMV)
virinae

Epithelia,
monocytes,
lymphocytes

Monocytes,
lymphocytes and
possibly others

Contact, blood
transfusions,
transplants,
congenital

6

Herpes
lymphotropic
virus
Human herpes
virus-7 (HHV-7)

Betaherpesvirinae

T lymphocytes
and others

T lymphocytes
and others

respiratory
route

Betaherpesvirinae

T lymphocytes
and others

T lymphocytes
and others

Unknown

Human herpes
virus-8 (HHV-8)

Gammaherpes- Endothelial cells
virinae

7

8

Gammaherpes- B lymphocyte,
virinae
epithelia

Unknown

Exchange of
body fluids

Note. Types of Herpes Viruses. From “Microbiology and Immunology Online,” by Hunt
R. Retrieved 06/01/2013 from http://www.microbiologybook.org/virol/herpes.htmhtm
University of South Carolina School of Medicine, Virology, Chapter 11 Herpes Viruses.
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Immunopathological Aspects of HSV Infection
The human immune system responds by activating its natural defense system to
remove detected foreign agents in the body. This defense mechanism against possible
antigens may induce disease-like symptoms such as fever and inflamed glands while
minimizing damage to the host (Banerjee & Rouse, 2007). However, immunopathology
may occur when the host tissue is damaged by chronic immune reaction (Whitley,
Kimberlin, & Prober, 2007). Recurrent lesions of HSV-2 in individuals with
immunocompromised immune system are an example of a chronic immune response that
can in fact increase the risk for other opportunistic conditions (Whitley et al., 2007). In
fact, HSV and other herpes viruses such as HHV-6 have been identified as inflammatorycausing lesion agents and the latter with possibly increasing the risk for multiple sclerosis
(Koelle & Corey, 2003; Swanborg, Whittum-Hudson, & Hudson, 2003). Prolonged and
chronic inflammatory reactions can cause damage to certain tissue sites or organs. For
example, HSV infections may cause impaired vision, retinitis, and ganglionitis and have
been associated with diseases like arthritis and Alzheimer’s disease (Pepose, 1991a,
1991b; Stuart, Summers, Morris, Morrison, & Leib, 2004). The immune response to
HSV-1 involves several mechanisms including the secretion of cytokines such as NK
cells, CD4+ and CD8+ lymphocytes, TNF- a, IFN-a, and IFN-y, which uphold antiviral
action (Kumel et al., 1982; Linnavuori & Hovi, 1987; Weidinger et al., 2000). The ability
of HSV-1 to interfere with the expression of major histocompatibility (MHC) class II
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antigen during its active state and the MHC class I gene during its latent state is what
allows the virus to evade the immune response; a phenomenon observed in HIV
(Halford, Balliet, & Gebhardt, 2004; Sawtell, Thompson, & Haas, 2006).
Association Studies Between Herpes Simplex Viruses and Diabetes
Although limited, the association between T2DM and CVD-prone pathogens have
been examined in prior studies (Roivainen et al., 2000; Zhu et al., 2001). Yuhua (2005)
and associates studied the relationship between HSV-1 and T2DM among 1,566 diabetic
and nondiabetic subjects. Results indicated a significant association between HSV-1 and
T2DM. Given that chronic inflammation is involved in the pathogenesis of T2DM, it is
assumed that inflammation is flare up by an infectious agent such as HSV-1 (Pickup,
2004). A recent study was conducted by Oke & Oke (2014) to investigate the prevalence
of HSV-1 and HSV-2 in diabetic and nondiabetic patients in a diabetic clinic in Nigeria.
The study population consisted of 320 patients aged 35-50. The prevalence of
hyperglycemia in this study was approximately 85% with fasting blood sugar (FBS)
ranging from 125 to 560 mg/dl. Approximately 50 (16%) had a normal glycemic reading
ranging from 55-90 mg/dl. Among the 270 diabetic patients, 55 (20.4%) were diagnosed
with ketonuria (as a result of insufficient insulin) and were seropositive to both, HSV-1
and 2. Diabetic patients with no ketonuria were also seronegative for HSV-1 and HSV-2.
This study shows a significant association between HSV-1 and 2 seropositivity and
diabetes; particularly among diabetic patients with hyperglycemia and ketonuria. Ketosisprone T2DM is one of the most common forms of diabetes in African populations since
1987, which researchers believe its onset is trigger by viral infection (Sobngwi et al.,
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2008; Tesfaye, Cullen, Wilson, & Woolley, 1991; Jun et al., 2003). These claims were
also supported by Tesfaye and associates (1991) who reported cases of diabetic
ketoacidosis induced by genital herpes. Similar results were reported by Sobngwi and
colleagues (2008) who conducted a study to determine if an association between ketosisprone T2DM and other herpes viruses exists. A study population consisting of 187 (81
ketosis-prone T2DM and 106 nonketosis T2DM) black patients of African origin were
compared to 90 nondiabetic control group. A high prevalence of ketosis-prone T2DM
and a very high prevalence (almost 6-fold higher) of HHV-8 infection among patients
with ketosis-prone T2DM (approx. 87.7%) was observed compared to a lower prevalence
of HHV-8 among nonketosis T2DM (15.1%) OR 39.9 [95% CI: 17.1-93.4] (P < .001)
and among the control group (40%) OR 10.7[95% CI: 4.9-23.4] (P < .001).
The association between herpes virus entry mediator (HVEM), a receptor for
HSV and cytokines, was studied in 840 obese individuals by Bassols et al. (2009).
HVEM gene expression was found significantly higher in obese than in nonobese
individuals (p < 0.0001). These results indicate a positive relationship between HVEM
and obesity suggesting that this receptor may be a causal factor in the pathogenesis of
obesity and inflammatory response (Bassols, Moreno, Ortega, Ricart, & Fernandez-Real,
2009). Additional evidence supporting these findings was documented in a retrospective
cohort study conducted by Shah and Hux (2003) to determine the risk of diabetic patients
to acquire an infectious disease. Researchers looked at diabetic and nondiabetic patients
in Ontario Canada at two points in time 1996 and 1999. The risk for acquiring an
infection among diabetic versus nondiabetic patients was OR 1.21 [99% CI 1.20-1.11]
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while attributable death among diabetic patients was up to OR 1.92 [CI 1.79 - 2.05].
These results provide additional evidence on possible increased susceptibility among
immune compromised individuals to infection.
Findings from a case-control study conducted by Roberts & Cech (2005b)
indicated that a person previously exposed to one of the most common herpes viruses,
CMV, has up to a 12 times greater chance of developing T2DM. Results also showed that
diabetic patients had a greater seroprevalence of IgG CMV antibodies (97.6%) compared
to nondiabetic patients (86.7%) with a statistical significance OR = 6.2 [95% CI: 1.1 –
36.0] (p < 0.05). Greater odds were observed in a subset of patients with diabetes who
had significantly more vascular complications than the controls OR = 12.4 [95% CI: 1.3
to 117] (p < 0.05). A linear trend between diabetes, seropositivity to CMV, and age was
also observed in this study. Given the association of atherosclerosis with diabetes and
CMV, these findings support the premise that CMV may be a common factor between
diabetes and CVD.
Association Studies between Herpes Simplex Viruses and Cardiovascular Disease
To examine the relationship between herpes simplex viruses and CVD, Mendy
and colleagues (2013) conducted a cross-sectional study with 14,415 participants of
NHANES 1999-2010, aged 20-49 years with a mean age of 34.3 years. Among the
participants, over half (51.3%) were seropositive for HSV-1, 7.5% were seropositive for
HSV-2 and 15.2% were seropositive to both HSVs. Results of this study indicated a
significant association of HSV-2 with CVD OR 1.56 [95% CI = 1.09-2.21]; however,
HSV-1 was not associated with CVD in this study OR 1.13 [95% CI = 0.79-1.62]. Yet,
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HSV-1 and HSV-2 have been found in human atherosclerotic plaque (Gyorkey, Melnick
Guinn, Gyorkey, & DeBakey, 1984; Friedman, Macarak, MacGregor, Wolfe, &
Kefalides, 1981; Nicholson, & Hajjar, 1998). Likewise, CMV, a well-studied marker for
atherosclerosis has been linked to endothelial dysfunction (Danesh, Collins, & Peto,
1997).
A prospective study conducted with 643 men to examine the association between
HSV and CMV and MI and stroke indicated no evidence of these two pathogens
increasing the risk for atherothrombotic. However, it has been suggested that perhaps
viral particles may play a role in the initial process, but not at the clinical phase of the
disease (Ridker, 1998, 1999). A population-based study with a similar sample size (515)
examined the role of HSV-1 and CMV in CHD patients (Sorlie et al., 2000). A significant
association between CMV and CHD with a higher risk in diabetic patients was reported
in this study. However, no association was found between HSV and CHD suggesting
some degree of disease-pathogen specificity (Sorlie et al., 2000). Nevertheless, while
most studies conducted with CVD patients have focused on a single pathogen, it has been
suggested that aggregate pathogen load may be associated with increased risk for CAD
(Fernandez-Real et al., 2007). Pathogen burden has also been associated with plaque
rupture and acute thrombotic occlusion, major risk factors for acute MI, as well as insulin
resistance, a well-known factor for CAD (Epstein, 2002; Fernandez-Real et al., 2007).
This premise has been extended by several prospective studies in which pathogen burden
was found to be predictive of CVD (Zhu et al., 2001). Zhu and associates conducted a
study with 124 middle-aged men to examine the effect of four pathogens: HSV,
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enteroviruses, CMV, and chlamydia pneumonia, as well as insulin resistance. A strong
association was observed in insulin resistance patients and seropositivity with multiple
pathogens though a weak association was observed with a single pathogen including
HSV. It should be noted that the small number of individuals who were seropositive for
HSV-1 and HSV-2 may have limited the study’s ability to find a significant association
with these two infectious pathogens.
In a cohort study of 890 patients who had CAD based on angiography, however,
IgG antibodies for CMV, HSV-1, HSV-2, Hepatitis A virus (HAV) and CRP levels were
found significantly higher in patients who subsequently developed MI (Zhu et al., 2009).
A similar study with contradictory results was conducted with 122 postmenopausal women who tested positive for prior exposure to multiple infectious agents
including C. pneumoniae, H. pylori, HSV, and CMV (Nabipour et al., 2006). Although
results showed little evidence of the association between baseline serology of studied
pathogens and risk for CVD, C. Pneumoniae has been implicated in chronic
inflammatory response leading to atherosclerotic lesion progression in other studies
(Altman, 2003; Campbell & Kuo, 2004; Grayston, Kuo, Campbell & Benditt, 1993; Wu
& Wu, 2006). Equally, the longitudinal Helsinki Heart Study, a coronary prevention trial
that monitor patients who suffered from myocardial infarction (MI) or coronary death
during the eight and a half year trial period, examined CRP levels and antibodies for
several viruses including HSV. Results from this study found higher levels of HSV-1 and
Chlamydia pneumoniae antibodies in studied cases. The CRP mean was higher in cases
in comparison to controls (4.4 versus2.0 mg/L: p < 0.001). The odds ratio for cases with
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high antibodies and CRP levels were 2.4 [95% CI 2.9-3.3] for HSV-1 and 5.4 [95%
CI2.4-12.4] for Chlamydia pneumoniae. The relative risk for high levels of antibodies for
HSV-1 was 2.05 (95% CI 1.15-3.67) in nonsmokers and 23.74 for smokers [CI1.588.86]. These findings demonstrate that high levels of antibodies of HSV-1 may be a
marker for active, recurrent infection and a potential trigger for inflammation reaction
increasing the risk for coronary heart disease (Benditt, Barrett, & McDougall, 1983;
Gyorkey et al., 1984; Hoffmeister et al., 2001; Ridker et al., 1998; Roivainen et al.,
2000).
A few seroepidemiological studies have also linked HSV-2 as a potential
cardiovascular pathogen; particularly, it has been implicated in atherosclerosis, CAD, and
MI (Espinola-Klein et al., 2002; Nicholson et al, 1998; Rupprecht et al., 2001). HSV-2,
however, have been associated with carotid wall thickening, vascular disease,
thrombogenic and atherogenic of host cells (Sorlie et al., 1994). These findings have been
extended by recent prospective studies specific to HSV-2. Sun et al (2004) investigated
the relationship between HSV-2 and hypertension by inducing inflammation, a co-factor
of HSV, in a cross-sectional study of 1,244 patients. The prevalence of HSV-2 IgG
seropositivity was significantly higher in subjects with hypertension than in the control
group (38.3% vs 29.8%, p = 0.002) and found to be an independent risk factor for
hypertension (Sun et al., 2004). Similar results were found in a study of 31 patients
undergoing coronary artery bypass. An association between inflammatory cells, cold
sores, and HSV-2 antigen was observed in biopsies (Sun et al., 2004).
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Summary
This literature review explored research in some areas of chronic diseases,
autoimmune inflammatory response and infectious agents including those tested in the
present study, HSV-1, HSV-2, and CMV. Current evidence demonstrates that
inflammation is a co-factor of both, chronic disease and infection. Although the role of
pathogens in the development of chronic disease is not well understood, studies that
examined the underlying autoimmune responses of infection suggest an increased risk for
developing inflammatory diseases. Alternatively, persons with chronic diseases may
develop susceptibility to infection. Despite the accumulating evidence that infectious
agents may predispose individuals to the development of chronic diseases,
seroepidemiological studies continue to fail in demonstrating a strong causality or
association between a single or multiple pathogens and disease development. Recent
studies have hypothesized that if infection causes T2DM or CVD, it is likely to be caused
by multiple pathogens. Other controversial area that remain to be explored is whether
multiple agents or recurrence of inflammation influence early infection.
In summary, conflicting results found in the current literature pose a challenge
when it comes to synthesizing results and generate inferences that apply to the general
population. There is urgency for additional clinical research and longitudinal studies to
better understand the activation of the immune system in response to inflammatoryinduced agents and/or mechanisms. Although some preliminary clinical research is
beginning to explore some possible mechanisms by which inflammation can be linked to
pathogenic response or a chronic condition, causal factors need to be established. The
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design for the present study was chosen based upon the existing literature relevant to this
study and data available and would not allow for determining causality. The next chapter
provides a description on methodology, instrumentation, study population, sample size,
and analysis used in this study.

Chapter 3: Research Method
Study Design and Approach
In this study, a population-based, cross-sectional design was used to determine
whether there was an association between two major chronic diseases, T2DM and CVD
and two herpes viruses, HSV-1, HSV-2. To evaluate whether burden of herpes infections
(having two or three herpes viruses) has an effect on T2DM or CVD, CMV was added to
the analysis of burden of infections. In addition, the relationship between (a) T2DM and
CVD and (b) selected inflammatory markers (CRP, homocysteine, and ferritin) was
examined. The primary risk factors for both diseases, as identified in the literature
review, were also evaluated in relationship to the dependent variables under study.
Twelve years of secondary data (1999-2010) were analyzed to evaluate disease
prevalence, trends, and associations. Although a cross-sectional design cannot determine
a causal relationship, this study was expected to add to the literature on the potential
association between the tested variables. Given the nature of the data, a nonexperimental,
correlational approach was used. Study participants were randomly selected by a national
survey and information on variables of interest were collected through three different
means: a self-reported questionnaire, a physical examination, and clinical data for each of
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the participants. These three data collection methods provided a means to confirm the
status of the disease and to validate the data.
Data Collection and Sample
This study used the NHANES data collected from 1999–2010. NHANES, which
began in 1999 and is conducted every 2 years, is a national probability survey conducted
by the National Center for Health Statistics, Centers for Disease Control and Prevention
(CDC, 2012). The survey is designed to estimate the prevalence of common chronic
conditions and associated risk factors in service of chronic disease prevention. NHANES
data are the product of a combination of (a) demographic, nutrition, and health-related
questions and (b) physical examinations that consist of laboratory tests and medical,
dental, and physiological measurements that are made by highly trained medical
personnel.
A national representative sample consisting of approximately five thousands U.S.
residents is collected by NHANES each year using a complex, multistage, cluster design.
Health topics collected by NHANES include but not limited to cardiovascular disease,
kidney disease, obesity, oral health, physical fitness, and sexually transmitted diseases
(CDC, 2012). A total of 99,806 participants were included in NHANES from 1999-2010,
from approximately 89 strata (selected surveyed areas) with 2–3 household units—or
primary sampling units (PSUs)—in each stratum. The final study sample consisted of
6,706 individuals, aged 20-49, for whom interviews and medical examinations were
completed, and for which laboratory results were available for all variables of interest.
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Selection of NHANES Participants and Setting
NHANES participants are selected through an algorithm that randomly selects
neighborhoods based on census information. Approximately 15,000 households are
screened, 3,500 are selected, and 5,000 residents from the selected households are
interviewed. Residents of household units are randomly selected and approached by
interviewers (health, research and academic professionals) to determine their eligibility.
If a resident agrees to be a part of the study they are scheduled for an interview. The
interview is conducted in their home and last approximately one hour. Responses are
recorded on a lap top computer. Individuals 60 and older, African Americans, Hispanics
and Asians are oversampled in order to increase representation of their population and
sample reliability (CDC, 2012). Participants also undergo a physical examination by a
team of health technicians, dentists and doctors in the Mobile Examination Center (MEC)
which consists of four connecting trailers containing high-tech medical equipment.
Health exams are given which include measurements of bone density, blood pressure,
weight and height. Urine and blood samples are collected and tests for health conditions
such as STIs, anemia, substance use and exposure to environmental chemicals.
Selection Criteria for Study Participants
NHANES serological test results for HSV-1 and HSV-2 were available for
individuals 14-49 years old. Serological data for adolescents 14-17 are restricted and not
available for public use. Additionally, some of the variables in question were collected
solely from individuals 20 years and older. As a result, this study was limited to
NHANES participants between the ages of 20 and 49 for which interviews, medical
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examination, and laboratory results for all variables of interest were completed.
NHANES participants whose answers were recorded as don’t know, refused, or missing
were excluded from the analysis. In addition, some analyses were limited to a specific
time intervals and subgroups for which the data were available. These include antibody
for CMV (data available from 1999-2004) and homocysteine (data available from 1999 to
2006).
Instrument and Materials
Secondary quantitative data from NHANES 1999-2010 were used in this study.
NHANES datasets can be accessed through the CDC website in the NHANES page.
NHANES begun in the 1960’s, and in 1999 became a continuous program examining
different health topics and behaviors among various populations. The survey is comprised
of sociodemographic, dietary and health related questions and also includes physical
examinations, urine and blood tests to determine the prevalence of major diseases and
risk factors. The household interview component contains a screener, family interview
and sample person questionnaire given to individuals in their home (CDC, 2012).
The Mobile Examination Center (MEC) Questionnaires consist of a MEC ComputerAssisted Personal Interview (MEC CAPI) and MEC Audio-Computer-Assisted Self
Interview (MEC A-CASI) where participants can answer questions without the
interviewer being present. Data is collected using a touch screen lap top computers with
electronic pens. Interviewers can easily submit information to data servers which are
available to NCHS staff within 24 hours. The CAPI and CASI programs contain built-in
quality assurance checks when unrealistic responses are entered. Validity and reliability
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for all questionnaires are pretested before implementation (CDC, 2012). Additionally,
laboratory techniques used from 1999 to 2010 to detect enzymes and antibodies to
studied agents were identical and therefore comparable for trend analysis.
Justification for Using NHANES Survey Data
NHANES is a national survey which data can be used to provide a measurement
of diagnosed and undiagnosed medical conditions and rates of diseases which can be
useful in developing public health interventions, programs and policies. NHANES is
distinctive because it combines survey data with physical examination and clinical data to
assess the health of the participants and increase the validity of findings. Additionally,
NHANES data has been systematically implemented since 1999 to report a U.S.
representative sample of health data. The survey contains information on several different
health variables which makes it appropriate for this study. NHANES findings have been
used to determine disease prevalence, develop national standards and health policies and
design health programs and services demonstrating its relevance and use for the
population. Table 3 lists dependent, independent, and covariates included in this study.

Table 3
List of Dependent, Independent & Covariates studied, NHANES 1999-2010
Dependent Variables

Independent Variables
of interest
Diagnosed T2DM
Herpes viruses
Diagnosed CVD
HSV-1 seropositive
HSV-2 seropositive
CVD related conditions CMV seropositive
CHD
CHF

Covariates
Age
Gender
Education Level
Race/Ethnicity
Household Income
BMI
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Angina
Heart Attack
MI
Stroke

Inflammation Markers Smoking Status
CRP
Hypertension
Homocysteine
Cholesterol
Ferritin

Selection of Studied Variables
Selection of study variables was based on research interest available in NHANES
1999-2012 surveys. Covariates were selected based on empirical evidence on risk factors
for both T2DM and CVD. Variables such as age, gender, education and race/ethnicity
were collected from survey interview data. Physical examinations such as height, weight
and BMI and laboratory blood tests for HSV-1 and HSV-2 antibodies were conducted by
MEC (CDC, 2012). Blood was drawn from the participant’s arm via venipuncture to
obtain laboratory results. In the laboratory, the blood is processed, stored and shipped to
different laboratories for analysis. The complete blood count (CBC) results are reported
in the MEC, and all other results are reported from NCHS to the participant. The volume
of blood drawn is determined by age. For 12 plus years, 115ml of blood is collected from
participants. Urine samples are collected from participants 6 years old and above.
Dependent Variables
T2DM
Self-report of T2DM was assessed by the following questions: Have you ever
been told by a doctor or health professional that you have diabetes or sugar diabetes?
How old were you when you were told that you had diabetes or sugar diabetes?
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Respondents input age at the time they were told. Additionally, participants were asked
about diabetes-related medication, respondents answered yes or no to questions such as
these: Are you now taking insulin?, For how long have you been taking insulin?, and Are
you now taking diabetic pills to lower your blood sugar? Only respondents who answered
questions with a yes or no were included in the analyses; missing values were excluded.
Clinical diagnosis of T2DM was assessed by evaluating major T2DM indicators.
Blood sample measures of plasma glucose (500uL/1mL) and glycohemoglobin A1C test
(400uL) were obtained from participants 12 years and older who were examined in the
morning sessions. A fasting glucose blood test was performed in all participants 12 years
and older who were examined in the morning session after a 9-hour fast. After the
venipuncture, participants are asked to drink 75 milligrams of Trutol® and to have a
second venipuncture two hours (±15 minutes) after the first venipuncture.
Diabetes was defined by at least one of the following criteria: (a) self-report of
diagnosis by a doctor or other health professional, (b) FBG ≥126 mg/dl, or (c) HbA1C
≥6.5%. Individuals without diabetes did not meet any of these criteria
CVD
For the purpose of this study, CVD was defined as self-report of diagnosis by a
doctor or other health professional of coronary heart disease, angina, heart attack,
congestive heart failure, or stroke. Self-report of CVD was determined by selected
questions under NHANES medical conditions. CVD questions focused on congestive
heart failure (CHF), coronary heart disease (CHD), angina (also known as angina
pectoris), heart attack (also called myocardial infarction or MI), and stroke.
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CVD questions are as follows:
Congestive heart failure questions: Has a doctor or other health professional told you
that you had congestive heart failure? How old were you when you were told that you
had congestive heart failure?
Congestive heart failure questions: Has a doctor or other health professional told you that
you had congestive heart failure? How old were you when you were told that you had
congestive heart failure?
Coronary heart disease questions: Has a doctor or other health professional told you that
you had coronary heart disease? How old were you when you were told that you had
coronary heart disease?
Angina questions: Has a doctor or other health professional told you that you had angina?
How old were you when you had angina?
Heart attack or MI questions: Has a doctor or other health professional told you that you
had a heart attack or MI? How old were you when you had a heart attack or MI?
Stroke questions: Has a doctor or other health professional told you that you had a
stroke? How old were you when you had a stroke? Only respondents who answered
questions with a yes or no were included in the analyses; missing values were excluded.
Independent Variables
The primary independent variables for this study include HSV-1 and HSV-2.
CMV was added as another independent variable to test the effect of burden of herpes
infections (HSV-1, HSV-2, and CMV) in T2DM and CVD. Secondary independent
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variables include three inflammatory markers, C-reactive protein (CRP), Homocysteine
and serum Ferritin. Evidence-based major risk factors were included as covariates.
HSV-1 and HSV-2 Seropositivity
To determine the serostatus for HSV-1 and HSV-2, blood samples of 500uL were
collected from individuals 14-49 years at the Medical Examination Center (MEC) and
tested for both HSV-1 and HSV-2 antibodies. However, only test results from
participants 18 to 49 years of age were available for public use. An enzyme immunoassay
(EIA) with specific glycoprotein (antigens) to differentiate between HSV-1 and HSV-2
antibodies was used; however, data for antibodies was limited to only few years.
Serostatus was recorded as positive or negative. Missing values were excluded.
HSV-1 and HSV-2 Self-reported
Self-reported for HSV-1 was not collected in NHANES. A single question to
determine HSV-2 history was asked to study participants, Has a doctor or other health
care professional ever told you that you had genital herpes? Due to the fact that genital
herpes can be caused by HSV-2 and HSV-1, individuals who reported being told they
have genital herpes were also matched with their serostatus for HSV-1 and HSV-2.
NHANES clinical data does not differentiate between HSV-1 and HSV-2 for genital
herpes. Missing values were excluded.
CMV
To determine the serostatus for CMV, blood samples of 350uL were collected
from persons aged 6 to 49 years and tested for CMV antibodies. CMV specific antibody
was measured with an ELISA assay. Analyses on CMV were limited to a time period of
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six years given that data were collected solely from 1999 to 2004. Test results for
participants aged 20 to 49 were available for public use and included in the study
analysis. Serostatus for CMV was recorded as positive or negative. Missing values were
excluded.
Inflammatory Markers
Inflammatory markers also known as biomarkers are useful clinical diagnostic
and prognostic tools for ruling out specific conditions. For example, elevated levels of
CRP, a protein synthesized by the liver, is an indication of inflammation present in the
body and has been used as a biomarker for the risk of CVD and T2DM (Ballantyne et al.,
2005; Davidson, 2011; Ridker et al., 2000; Watson et al., 2012). Interleukin or IL-6, a
protein-coding gene, functions with inflammation in response to harmful stimuli such as
infection (Ridker et al., 2000I). L-6 marker was not collected by NHANES and therefore
not included in the study. Fibrinogen, a protein synthesized by the liver, helps to stop
clots to form by converting thrombin into fibrin and may indicate a risk for diabetes.
Fibrinogen data was collected for only few years and therefore not included in study
analysis. Elevated levels of Ferritin, a protein that controls the levels of iron in the blood,
may be an indication of inflammation, heart failure, diabetes and other conditions
(Oshaug et al., 1995; Ridker et al., 2000). Elevated levels of Homocysteine, an amino
acid found in the blood plasma, may increase the risk for heart disease (Ridker et al.,
2000).
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CRP
Approximately 300uL of blood samples from individuals 3 years and older were
used to measure the levels of CRP. The following predictive values were used for CVD:
Normal levels of CRP range from 0 to 1.0 mg/dl. Elevated high sensitivity CRP (hsCRP)
levels associated with CVD and other chronic diseases. Any hsCRP level less than 1.0
mg/L is considered low risk; average risk is considered between 1.0 and 3.0 mg/L; and
elevated hsCRP levels and highest risk are considered more than 3.0 mg/L. The median
concentration of the study population was used as the cut off for both CVD and T2DM
when applicable.
Homocysteine
Plasma homocysteine is a nonprotein amino acid. Blood samples of 1.25mL were tested
from individuals 1 year and older. Analysis for homocysteine were limited to a time
interval of eight years given that data was collected only from 1999 to 2006. For the
purpose of this study, the median value of homocysteine in the study population was used
as a cut off when applicable.
Ferritin
The level of serum ferritin is directly related to the amount of iron stored in the body.
Blood samples of 1.25mL were tested from individuals 1 year and older. Normal values
of Ferritin may vary from lab to lab and in the clinical field in general. For this study, the
median value of ferritin in the study population was used as a cut off when applicable.
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Covariates
Age
Age was determined in the questionnaire by the date of birth given by
participants. Respondents who answered don’t know or refused to answer were coded as
missing and excluded from the analysis. Analyses were limited to participants ages 20-49
due to data availability.
Gender
Participants were asked in the questionnaire to select if they were male or female.
Respondents who answered don’t know or refused to answer were coded as missing and
excluded from the analysis.
Education Level
Respondents were asked in the questionnaire: What is the highest grade or level
of school that you have completed or the highest degree you have received? Education
levels were divided into two categories: individuals who completed high school and those
who had college level. Respondents who answered don’t know, refused or the answer
was coded as missing were excluded from the analysis.
Race/Ethnicity
Respondents were asked in the questionnaire: What race do you consider yourself
to be? NHANES used five categories: nonHispanic White, nonHispanic Black, Mexican
American, Other and Other Hispanics and could only select one. Respondents who
answered don’t know, refused or answer was coded as missing were excluded from the
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analysis. Due to frequency distribution limitations with multi-categorical variables, race
was recategorized as nonwhites versus whites for binary logistic regression.
Household Income
In the questionnaire, family was described as: Individuals and groups of
individuals who are related by birth, marriage or adoption. Stepchildren, parents or
siblings are included. It also includes unmarried partners if they have a biological or
adoptive child in common. Participants were asked about the total income for you and
your family members in the last calendar year- including income from all sources we
have just talked about such as wages, salaries, social security or retirement benefits, help
from relatives and so forth. Can you tell me that amount before taxes? Respondents
entered the amount of income. In this study household income was categorized as follow:
income from 0 to 24, 999; income from 25, 000 to 54, 999; income over 55, 000.
Respondents who answered, don’t know, refused or answer was coded as missing were
excluded from the analysis.
BMI
The body mass index (BMI) was calculated using participants’ body weight and height
(weight divided by height). In this study, BMI <25 was categorized as normal weight;
BMI ≤25 and <30 as overweight; and BMI≥30 was considered obese. Respondents who
answered, don’t know, refused, or answer was coded as missing were excluded from the
analysis.
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Smoking Status
Smoking status was determined by asking, have you smoked at least 100
cigarettes in your entire life? Respondents answered yes or no. They were also asked, Do
you now smoke cigarettes: every day, some days or not at all? Respondents answer yes or
no. Only respondents who answered questions with a yes or no were included in the
analyses. Smoking status was categorized in the analysis as follows: never smoke; past
smoker; and current smoker.
Hypertension /Blood Pressure
Self-reported high blood pressure of the participants was assessed by the
following questions: Have you ever been told by a doctor or other health professional that
you had hypertension, also called high blood pressure? Respondents answered, yes or no
to questions such as Have you been told on 2 or more different visits that you had
hypertension, also called high blood pressure?, because of your blood pressure have you
been told to take prescribed medicine? Are you now taking prescribed medication?
Respondents were also asked, what age were you told that you had high blood pressure?
Only respondents who answered questions with a yes or no were included in the analyses.
Physical measurements of systolic and diastolic BP consisting of up to 4 different BP
readings in different time intervals were collected from survey participants. For the
purpose of this study, the 2nd reading was selected as a better estimate for measuring BP
among participants.
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Cholesterol
Self-reported cholesterol levels were assessed. Respondents answered yes or no to
the following questions: Have you ever been told by a doctor or other health professional
that your cholesterol was too high? To lower your blood cholesterol, have you ever been
told by a doctor or other health professional to take prescribed medicine? and Are you
now following this advice to take prescribed medicine? Only respondents who answered
questions with a yes or no were included in the analyses.
For physical examinations total cholesterol, HDL- cholesterol, LDL-cholesterol
were measured through blood lipid levels of 1mL from individuals 12 and older. Total
cholesterol was calculated from totals of HDL and LDL levels. For analysis purposes, the
median of total cholesterol, HDL and LDL values in the study population were used.
Statistical Analysis
This study employs secondary data from the CDC NHANES database and utilizes
a cross-sectional design, which provides the means for conducting descriptive and
inferential analysis. First, simple descriptive statistics to examine the distribution of the
study sample (N=6,706) such as means, standard deviations, and proportions (when
appropriate) for the main outcome variables (T2DM and CVD) and explanatory variables
(demographic and clinical variables) were applied. Second, a binary analysis and chisquare test was used to determine the relation between the two dependent variables and
categorical predictors. Given that NHANES provides a large representative sample for
conducting secondary research studies, statistical hypothesis testing power is not a
concern for the analyses needed in this study. Multiple logistic and stepwise regression
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analyses adjusting for demographic and clinical variables was applied for confounding
factors using continuous waves of NHANES data from 1999 to 2010.
All statistical analyses were performed in SAS-Callable SUDAAN, Release
11.0.1. (RTI, 2013). A reference table that included all study variables names, SAS data
files, and relevant codebook and documentation was used for accuracy and validity.
NHANES data files were imported from the CDC NHANES website located at
http://www. NCHS.gov and saved in a preassigned library in SAS v9.3. (SAS, 20002004). Once all of the needed variables were downloaded into the SAS library, data were
merged by SEQN ID, recoded and categorized when necessary for analysis purposes.
Analytical recommendations from NHANES for sample weights and variables of interest
were used. Descriptive analysis was performed on independent, dependent, and covariate
variables. When necessary and applicable, study variables were dichotomized at the
median value defined by the studied population into either low to normal or average to
high levels. The high and average levels of CRP were combined given that the frequency
in the high group was small, and there were too many missing once the weight variable
was applied. A similar approach was used with ferritin levels due to small sample size in
the high and low levels of ferritin for men and women. Therefore, CRP was recategorized
into high or average levels versus low or normal levels, and ferritin levels for men and
women were combined and recategorized as high versus low and normal versus low in
the multivariate regression analyses.
To determine the relationship between two categorical variables, a standard
Pearson’s Chi-square test was performed and to determine the relationship between two
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continuous variables, the standard t-test was used. To test the hypothesis of association
between HSV and T2DM and CVD, logistic and stepwise regression analyses were
performed (Draper, & Smith, 1981; Hocking, 1976). Adjustments were made to control
for potential confounding factors and calculate the adjusted odds ratio and respective
95% confidence interval (CI). Primary independent variables and covariates were entered
into four different models. In the 1st model, crude rates for all independent variables and
covariates were calculated. In the 2nd model, adjusted rates for all the independent
variables and covariates were calculated. In the 3rd and 4th models, the most predictive
independent variables and covariates were included in each group. The 3rd and 4th models
consisted of different stages. At first stage, the primary independent variable, HSV-2, was
entered into the model. Then a forward stepwise regression was performed to add the
most predictive demographic variables (second stage). Significant demographic variables
such as age, gender and household income were added into the model at this stage. After
adjusting for these variables, additional clinical variables were added into a final model
(third stage). Since the final model (column 4 in odds ratio tables for T2DM and CVD)
removes the effect of all possible confounders, this model provides the best effect
estimates. Overall associations were represented by values p ≤ 0.10, p ≤ 0.05, p < 0.01.
The PROC RLOGIST (RTI, 2013) was used to model the risk of T2DM and CVD
as a function of HSV-1 and HSV-2; HSV (the combination of HSV-1 and HSV-2 was
defined as 0 = neither HSV-1 nor HSV-2, 1 = HSV-1 or HSV-2, 2 = HSV-1+HSV-2,
3 = HSV-1+HSV-2+CMV); and burden of herpes infection was defined as 0, 1, 2, 3
adjusted by demographic covariates, age, gender, race, educational status, household
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income, and smoking, and clinical covariates blood pressure, body mass index (BMI),
blood cholesterol level, C reactive protein (CRP) and ferritin (Tables 4, 5, 6 and 7). In
addition, the PROC CROSSTAB (RTI, 2013) was used to evaluate the prevalence
difference of T2DM and CVD among different categories of explanatory variables
without adjusting by age, and the PROC DESCRIPT (RTI, 2013) was used to evaluate
the prevalence difference of T2DM and CVD among different categories of explanatory
variables adjusted by age. For all of three procedures above, the nest, weight and subpopn
statements were used (Tables 2 and 3). The nest statement with strata (sdmvstra) and
PSU (sdmvpsu) was used to account for the design effects. The weight statement with
weight variable FASTWGT was used to account for the unequal probability of sampling
and nonresponse. The subpopn statement was used to select the sample individuals 20 or
older and less than 50 years (20 ≤ age < 50) because only those individuals are of interest
in this study.
The research questions are listed below again for review.
H11: Is HSV-1 infection associated with higher risk of developing T2DM?
H01: HSV-1 infection is not associated with higher risk for T2DM.
H12: Is HSV-2 infection associated with higher risk for of developing T2DM?
H02: HSV-2 infection is not associated with higher risk for T2DM.
H13: Is HSV-1 infection associated with higher risk of developing CVD?
H03: HSV-1 infection is not associated with higher risk for CVD.
H14: Is HSV-2 infection associated with higher risk of developing CVD?
H04: HSV-2 infection is not associated with higher risk for CVD.
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H15: Is having a higher burden of pathogens (HSV-1 + HSV-2+CMV) associated with a
higher risk of developing T2DM and/or CVD?
H05: A higher burden of pathogens is not associated with higher risk for T2DM and/or
CVD.
Bias and Delimitations
Given that this study utilized data collected from a cross-sectional design, the study
cannot prove causality. Only participants whose data were available between the ages of
20 and 49 with positive serology test for HSV-1 and HSV-2 and diagnosed with T2DM
and CVD were included in the study. Some analyses were restricted to subpopulations for
which the studied variables were collected. While data for HSV, T2DM and CVD were
collected for 12 years period (1999-2010), serological status for other herpes viruses
associated with inflammatory diseases such as CMV were available only for 4 years
(1999-2004), which limited the opportunities for comparison and correlation analysis. In
addition, data for some of the inflammatory markers were not collected consistently for
the 12 years period; therefore, some analyses were restricted by this limitation.
Potential Bias
Selection Bias
NHANES selects survey participants randomly from a large cross-sectional study
sample, which allows for making inferences for the general population. As a result,
selection bias is not a concern.
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Information Bias
Self-report bias may be a limitation of NHANES data given that the interview
questions are based on information recall of the participants. Participants may provide
biased information when he or she cannot recall or may modify the information when
asked by the interviewer. Nevertheless, for the purpose of this study, the main variables
of interest (HSV, CMV, T2DM, CVD, CRP, homocysteine, serum ferritin) were
measured by laboratory and examination results rather than self-report alone. NHANES
laboratory methods are conducted with high performance instruments and following strict
protocols.
Confounding
A multivariate analysis was performed on variables of interest, which allows
identifying potential cofounder factors.
Type I and Type II error
To control for type I error, a margin of error was set at alpha 0.05, with a
probability of accuracy of 95%. Since a large sample size of 6,706 was used in the
present study, type II error is not a concern.
Ethical Considerations
NHANES survey has ongoing Institutional Review Board (IRB) approval through
the National Center for Health Statistics (NCHS) Research Ethics Review Board. The
IRB ensures that ethical, biomedical and behavioral research best practices involving
humans are in place before, during and after research studies are conducted with humans.
By law, NHANES adheres to a rigorous review process in making certain that human
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subject’s identity is kept confidential and anonymous. In fact, all personal identifiers are
removed from NHANES data prior publishing. Written consent is obtained from each
survey participants. In a case of a minor, consent is obtained from parents or legal
guardian. Given that I used publicly available secondary data with no link to personal
identifiers, this study poses no physical or emotional risk or benefit directly or indirect to
survey participants (CDC, 2012). IRB approval number for this study is 12-09-130075602.
Summary
This study used a cross-sectional population based designed and a large sample
size from the CDC NHANES (1999-2010) dataset. Independent and dependent variables
as well as covariates were selected based on a comprehensive literature review. Given the
type and number of variables selected for this study, chi square was applied in univariate
analysis whereas multivariate logistic and stepwise regression analyses were employed to
examine the relationship between HSV and T2DM; the relationship between HSV and
CVD; and the effects of burden of infections (having more than one herpes virus) on
T2DM and CVD. The relationship between T2DM and CVD and selected inflammatory
markers and covariates was also evaluated. Several statistical models were used to test
study hypotheses of association. Adjustments for possible confounding factors were
performed in all the analyses. Lastly, since this study used 12 years of data from a
national representative sample, results and findings from this study can be applied to the
general population.
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Chapter 4: Results
Introduction
This study examined whether being HSV-1 or HSV-2 seropositive increases the
risk of developing T2DM and/or CVD; and whether being seropositive to both HSVs or
to three herpes viruses (HSV and CMV) increases the risk of developing T2DM and/or
CVD. Further, this study evaluated whether a relationship exists among T2DM and CVD
and CRP, serum ferritin, and homocysteine. It used a representative sample from
participants in the United States. A cross-sectional design was used with NHANES data
from 1999-2010. During that period, 99,806 participants were studied. The sample size
for this study consisted of 6,706 participants, aged 20-49, who met the criteria and data
from interviews, medical examination, and laboratory were available. Also evaluated
were the estimates for the prevalence of each of the primary independent and dependent
variables as well as for the covariates. Chapter 4 discusses the study results; important
findings are presented in graphs and tables, which include the characteristics and
distribution of the study population, the distribution of the herpes viruses understudy, the
prevalence of T2DM and CVD in the sample, and the relationship among T2DM and
CVD and HSV-2. The findings are summarized at the end of the chapter.
Demographic and Health Characteristics of Study Population
The distribution of the study population is described in Table 4. The average age
was 35 years with slightly more between 35-49 years old (52.6%) than 20-34 years old
(47.4%). The sample was equally divided between males (49.7%) and females (50.3%).
The majority of participants were nonHispanic Whites (65.8%), followed by Hispanics
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(16.9%), nonHispanic Blacks (12.5%), and other racial populations (4.9%). The
participants were well educated, with more than half having earned a college degree
(57.8%) and only slightly less having completed high school (42.3%). Most participants
had incomes well above poverty, with nearly half earning annually more than $55,000
(47.0%) and about one-third between $25,000-54,000 (31.9%). The majority of
participants were nonsmokers (55.2 %). Clinical data indicated that nearly all of the
participants (91.8%) were not hypertensive; however, only 36.9% had a normal BMI
(less than 25). The rest of the participants were either overweight (32.4% with a BMI
25-29) or obese (30.8 % with a BMI ≥ 30). Nearly all participants had low-normal CRP
levels (90.5 %). Overall, ferritin levels for participants were normal with the majority of
men (83.3 %) and women (94.7%) in the low to normal range. Most participants had
normal (97.3%) homocysteine levels and a few (2.7%) had moderate levels. Since no
participants had elevated levels of homocysteine, this marker was excluded from
association analyses. More than half of the participants had cholesterol levels that were
desirable (61.0%); about one-quarter had borderline (26.9%) and only 12.0 % had high
cholesterol levels.
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Table 4
Demographic and Health Characteristics, NHANES, 1999-2010
Characteristics
Total Population
Age Mean
Gender
Male
Female
Race/Ethnicity
NonHispanic White
NonHispanic Black
Hispanic
Other
Age (years)
20~34
35~49
Education
High School
College or higher
Household Income
<25,000
25,000~54,000
>55,000
Smoking Status
Nonsmoker
Smoker
Hypertension
Yes
No
BMI(kg/m2)
<25 (normal)
25~29 (overweight)
≥30 (obese)
CRP Levels
Low-Normal
Average
High
Ferritin Levels (Men)
Low

nα
6706

Percentage (95% CI)
34.92 [34.58,35.26]

3106
3600

49.68 [48.63,50.73]
50.32 [49.27,51.37]

2931
1376
1958
441

65.80 [63.06,68.44]
12.47 [11.00,14.12]
16.85 [14.84,19.06]
4.88 [3.98,5.98]

3401
3305

47.37 [45.49,49.27]
52.63 [50.73,54.51]

3325
3373

42.25 [39.94,44.60]
57.75 [55.40,60.06]

1014
1347
1522

21.11 [18.99,23.40]
31.85 [29.36,34.45]
47.04 [44.16,49.94]

3884
2817

55.23 [53.17,57.28]
44.77 [42.72,46.84]

502
5360

8.25 [7.54,9.03]
91.75 [90.97,92.47]

2223
2213
2201

36.87 [35.42,38.35]
32.37 [30.87,33.92]
30.76 [29.25,32.30]

5949
651
80

90.50[89.77,91.19]
8.32 [7.62,9.08]
1.18 [0.88,1.58]

9

1.05 [0.47,2.32]
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Normal
881
82.25 [79.23,84.92]
High
160
16.69 [14.16,19.58]
Ferritin Levels (Women)
Low
779
20.28 [18.69,21.96]
Normal
2133
74.46 [72.46,76.37]
High
140
5.26 [4.30,6.43]
Homocysteine Levelsb
Normal
2003
97.33 [96.28,98.09]
Moderate
46
2.67 [1.91,3.72]
Elevated
0
Cholesterol Levels
< 200 (normal)
3936
61.03 [59.60, 62.44]
200~239 (borderline)
1849
26.93 [25.65,28.26]
≥240 (high)
870
12.04[11.00,13.15]
α
Data are missing for all variables except for age, gender, and race/ethnicity.
b
Data available only for 1999-2006, homocysteine was excluded from association
analyses.
Distribution of Herpes Viruses
Overall, a decline in all three herpes viruses (HSV-1, HSV-2, CMV) was
observed in this sample population from 1999 (HSV 62.4%, 23.7%) to 2010 (HSV
54.2%, 17.2%) respectively (Figure 4). A decline was also observed in CMV from 1999
(56.7%) to 2004 (53.0%). A similar trend was observed among the participants who were
seropositive to both, HSV-1and HSV-2 (14.8% in 1999) to (10.6% in 2010) and among
the participants who were positive to HSV and CMV (11.3% in 1999) to (8.5% in 2004).
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Figure 4. Percentage of participants seropositive for HSV-1, HSV-2, HSV-1+HSV-2,
CMV, and all three herpes from 1999-2010 in this U.S. population sample. Data for
CMV and burden of infection (three herpes viruses HSV and CMV) is not available after
2004.
In this study, more females than males were seropositive to all herpes virus
infections, with females having almost double the number of HSV-2 infections, 990
(26.4%) vs 499 (13.45) and HSV-1and HSV-2 infections, 669 (16.5%) vs 309 (7.55) than
males (Figure 5). A slightly difference was observed in the proportions of HSV-1 and
CMV among females, 2,391 (61.7%) vs 1,144 (62.1%) and among males, 1,932 (56.9%)
vs 823 (47.9%) respectively.
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Figure 5. Number of participants seropositive for HSV-1, HSV-2, HSV-1and
HSV-2, and CMV by gender from 1999-2010. CMV data only available from 1999-2004.
Results of this study indicated that CMV and HSV-1 were predominantly high
across all racial groups (Figure 6). Particularly, HSV-1 was high among Hispanics
(79.2%), followed by other race groups (77.9%), nonHispanic Blacks, and nonHispanic
Whites (51.8%). Similarly, CMV was higher among other ethnic populations (84.6%)
and Hispanics (80.9%), followed by nonHispanic Blacks (77.7%). CMV was far less
common among nonHispanic Whites (43.0%). In comparison to all racial groups, a
higher proportion of nonHispanic Blacks were seropositive to HSV-2 (46.7%) and HSV1and HSV-2 (30.0%), followed by other racial groups (HSV-2, 29.2%) and (HSV1+HSV-2, 23.4%).
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Figure 6. Percentage of participants seropositive for HSV-1, HSV-2 and CMV by
ethnicity from 1999-2010. CMV data only available from 1999-2004.

All herpes virus infections were higher among individuals between the ages of 3549, with this group having almost twice the number of HSV-2, 976 (26.3%) vs
513(12.9%) and over twice the number of HSV-1and HSV-2, 674(16.6%) vs 304(7.0%)
(Figure 7). A slightly difference was observed between individuals aged 20-35 and 35-49
that were seropositive to HSV-1, 2,027 (53.3%) vs 2,296 (64.8%) and CMV, 954 (51.3%)
vs 1013 (58.3%) respectively.
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Figure 7. Percentage of participants seropositive for HSV-1, HSV-2 and CMV by age
groups from 1999-2010. CMV data only available from 1999-2004.
Prevalence of T2DM and CVD by Selected Health Characteristics
The prevalence of T2DM and CVD among selected characteristics in the study
sample was examined using Pearson chi-square test (Figure 5). An elevated prevalence of
T2DM was observed in gender, race/ethnicity, age, household income, hypertension, and
BMI. Particularly, the age-adjusted prevalence of T2DM was significantly higher in
males 5.13% [95% CI=4.14, 6.35] than in females 3.70% [95% CI = 2.97,4.60];
significantly higher among Hispanics 6.62% [95% CI = 5.03, 8.66], followed by other
racial groups, 6.22% [95% CI = 3.83, 9.95]; and nonHispanic Blacks 6.12% [95%
CI=4.89, 7.64] compared to nonHispanic Whites, 3.51% [95% CI = 2.74,4.49]. T2DM
was over three times higher in individuals aged 35-49, 6.63% [95% CI = 5.53, 7.93] than
among aged 20-34, 1.78% [95% CI = 1.36, 2.34]; significantly higher among individuals
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with a household income between 25,000 and 54,999, 6.22% [95% CI = 4.53,8.48], and
with an income less than 25,000 6.06% [95% C I= 4.34, 8.39] than among individuals
with income ≥55,000; and more than two fold higher among individuals with
hypertension 9.44 [95% CI = 6.46, 13.6] than those without hypertension 3.72%
[95% CI=3.08,4.49]. Higher prevalence was found among obese individuals with a BMI
≥30 8.80% [95% CI = 7.36, 10.5]; followed by overweight individuals with a BMI 25-29
2.91% [95% CI = 2.14, 3.95] than among individuals with a BMI ≤ 25. However, no
difference was observed in the prevalence of T2DM and education, smoking status, or
cholesterol levels.
Similarly, the age-adjusted prevalence of CVD was found higher among
individuals aged 35-49, 3.60% [95% CI = 2.89,4.48] than among the younger group; with
a household income less than 25,000, 3.82% [95% CI = 2.40,6.02]; followed by
individuals with a household income between 25,000-54,999, 2.92% [95% CI=1.99,4.25]
than among individuals with an income ≥ 55,000; with hypertension 3.66% [95%
CI=2.31, 5.76] than among individuals without hypertension; among obese individuals
(BMI ≥30), 3.39% [95% CI = 2.58, 4.44], followed by individuals overweight (BMI
between 25-29) 2.12% [95% CI = 1.49, 2.99] than among individuals with a BMI ≤25. In
contrast to T2DM, CVD was significantly higher among individuals with a high school
education 3.00% [95% CI = 2.35, 3.84] compared to those with a college or higher
degree 1.80% [95% CI = 1.31, 2.48]; and among individuals that smoke or are past
smokers 3.65% [95% CI = 2.90, 4.59] in comparison to those that never smoke. The
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prevalence of CVD was not significantly different by gender, race/ethnicity, or
cholesterol level.

Table 5
Prevalence (%) of Reported T2DM and CVD among U.S. 20 to 49 Years Old by Selected
Characteristics, NHANES, 1999-2010
Characteristics

Gender
Male
Female
Race/Ethnicity
NonHispanic White
NonHispanic Black
Hispanic
Other
Age (years)
20~34
35~49
Education
High School
College or higher
Household Income
<25,000
25,000,54,000
>55,000
Smoking Status
Never smoke
Past or current
Smoke
Hypertension
Yes
No
BMI(kg/m2)
<25
25,29

T2DM
Unadjusted
(95%CI)
**
5.01 [4.03,6.20]
3.67[2.95,4.57]
***
3.57[2.79,4.56]
5.90[4.72,7.36]
5.72[4.28,7.61]
5.94[3.63,9.59]
***
1.78[1.36,2.34]
6.63[5.53,7.93]

T2DM
Age-Adjusted
(95% CI)
**
5.13[4.14,6.35]
3.70[2.97,4.60]
***
3.51[2.74,4.49]
6.12[4.89,7.64]
6.62[5.03,8.66]
6.22[3.83,9.95]
***
1.78[1.36,2.34]
6.63[5.53,7.93]

CVD
Unadjusted
(95%CI)

CVD
Age-Adjusted
(95% CI)

2.12[1.64,2.75]
2.39[1.78,3.21]

2.19[1.68,2.83]
2.41[1.79,3.24]

4.20[3.44,5.11]
4.64[3.75,5.72]

2.39[1.82,3.13]
2.79[2.01,3.84]
1.60[1.10,2.32]
1.46[0.61,3.46]
***
0.77[0.51,1.17]
3.60[2.90,4.48]
**
2.89[2.26,3.69]
1.80[1.31,2.48]
***
3.43[2.16,5.43]
2.68[1.82,3.92]
1.56[1.00,2.46]
***
1.05[0.74,1.50]
3.75[2.98,4.72]

2.34[1.78,3.07]
2.93[2.15,3.99]
1.73[1.18,2.52]
1.59[0.66,3.78]
***
0.77[0.51,1.17]
3.60[2.89,4.48]
**
3.00[2.35,3.84]
1.80[1.31,2.48]
***
3.82[2.40,6.02]
2.92[1.99,4.25]
1.45[0.92,2.27]
***
1.10[0.77,1.56]
3.65[2.90,4.59]

4.62[3.78,5.62]
4.14[3.29,5.20]
**
5.48[3.85,7.73]
5.81[4.25,7.89]
2.98[1.97,4.50]

4.79[3.96,5.79]
4.14[3.28,5.21]
**
6.06[4.34,8.39]
6.22[4.53,8.48]
2.77[1.81,4.22]

4.01[3.30,4.87]
4.75[3.84,5.85]
***
10.48[7.60,14.28]
3.59[2.97,4.33]
***
1.31[0.87,1.98]
2.96[2.18,4.01]

***
9.44[6.46,13.6]
3.72[3.08,4.49]
***
1.46[0.96,2.20]
2.91[2.14,3.95]

**
4.79[3.01,7.54]
2.03[1.57,2.61]
***
1.11[0.70,1.75]
2.16[1.52,3.06]

**
3.66[2.31,5.76]
2.11[1.63,2.71]
***
1.21[0.75,1.94]
2.12[1.49,2.99]
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≥30
Cholesterol Levels
< 200
200-239
≥240

9.08[7.60,10.83]

8.80[7.36,10.5]

3.52[2.67,4.62]

3.39[2.58,4.44]

4.04[3.32,4.91]
4.41[3.23,5.99]
5.28 [3.79,7.31]

4.52[3.70,5.50]
4.13[3.04,5.60]
4.73[3.38,6.59]

2.09[1.63,2.68]
2.23[1.53,3.24]
2.96[1.76,4.93]

2.34[1.83,2.99]
2.07[1.42,3.00]
2.31[1.37,3.87]

*p < 0.10, ** p < 0.05, ***p < 0.01

The prevalence of T2DM and CVD by each of the herpes virus infections and
selected inflammatory markers is illustrated (Table 6). Results indicated that the
prevalence of T2DM and CVD was significantly higher among individuals seropositive
to HSV-2, 5.54% [95% CI = 4.36, 7.01] and 3.32% [95% CI = 2.36, 4.65] respectively,
but not to HSV-1 or CMV. Age-adjusted prevalence of T2DM was significantly elevated
among individuals with average to high CRP levels 10.9% [95% CI = 8.11, 14.5] than
individuals with low-normal levels 3.63% [95% C I= 3.05, 4.33]; among males with high
ferritin levels 7.85% [95% CI = 3.68, 15.96] than males with normal levels 5.32% [95%
CI = 3.34, 8.37] and among females with high levels 12.6% (95% CI = 6.11, 24.07).
There was no data for low ferritin levels among males. Further, the prevalence of CVD
was higher among females with high 4.85% [95% C I= 2.53, 9.09] ferritin levels. No
relationship was observed between the prevalence of CVD and CRP, male’s ferritin
levels, or homocysteine neither between T2DM and homocysteine levels. There was no
data of elevated homocysteine levels for T2DM or CVD; therefore, homocysteine was
excluded from logistic regression analyses.
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Table 6
Prevalence (%) of T2DM and CVD Among U.S. 20 to 49 Years Old by Herpes Viruses
Infections and Selected Inflammatory Markers, NHANES
Characteristics

T2DM
Unadjusted
(95%CI)

HSV-1
Yes
4.56[3.79,5.48]
No
3.86[2.96,5.02]
HSV-2
***
Yes
6.15[4.87,7.75]
No
3.80[3.13,4.62]
a
CMV
Yes
4.30[3.08,6.00]
No
4.27[2.97,6.09]
CRP
***
Low-Normal
3.56[2.99,4.24]
Average to High
11.1[8.21,11.9]
Ferritin Levels
**
(Males)
Low
0.00
Normal
5.11[3.23,8.00]
High
8.93[4.06,18.52]
Ferritin Levels
***
(Females)
Low
2.36[1.55,3.57]
Normal
3.32[2.47,4.45]
High
12.15[7.08,20.08]
Homocysteine
Levelsb
Normal
4.05[2.94,5.56]
Moderate
7.42[3.04,17.04]
Elevated
0.00
*p < 0.10, ** p < 0.05, ***p < 0.01
a
Data available only for 1999-2004
b
Data available only for 1999-2006

T2DM
Age-adjusted
(95% CI)

CVD
Unadjusted
(95%CI)

CVD
Age-Adjusted
(95% CI)

4.40[3.66,5.29]
4.26[3.24,5.57]
***
5.54[4.36,7.01]
4.06[3.32,4.96]

2.44[1.90,3.11]
2.01[1.47,2.75]
***
3.96[2.82,5.52]
1.85[1.46,2.33]

2.36[1.85,3.01]
2.29[1.67,3.15]
***
3.32[2.36,4.65]
1.97[1.56,2.49]

4.16[3.03,5.70]
4.47[3.08,6.45]
***
3.63[3.05,4.33]
10.9[8.11,14.5]
**

1.97[1.31,2.96]
1.90[1.13,3.19]

1.92[1.28,2.85]
2.05[1.20,3.49]

2.07[1.65,2.59]
3.84[2.44,6.00]

2.11[1.69,2.64]
3.74[2.41,5.76]

0.00
5.32[3.34,8.37]
7.85[3.68,15.96]
***

0.00
2.32[1.32,4.03]
3.67[1.53,8.53]
*

0.00
2.39[1.36,4.19]
2.90[1.18,6.93]
*

2.49[1.62,3.80]
3.38[2.53,4.51]
12.56[6.11,24.07]

1.72[0.82,3.57]
2.26[1.52,3.34]
6.34[3.30,11.85]

1.77[0.84,3.70]
2.32[1.56,3.44]
4.85[2.53,9.09]

4.10[2.99,5.62]
5.74[2.24,13.91]
0.00

2.81[1.94,4.07]
5.66[1.56,18.54]
0.00

2.88[1.97,4.17]
6.66[1.63,23.50]
0.00
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Relationship Between T2DM and HSV
The relationship between T2DM and HSV-2 as well as demographic and clinical
variables was explored (Table 7). Results from the logistic regression analysis (crude
odds ratios) showed that T2DM was associated with HSV-2, age, gender, race, household
income, blood pressure, BMI, CRP, and ferritin. Specifically, T2DM was 1.66 times
more likely to occur among individuals who were HSV-2 positive than among
individuals who were not (p = 0.0010) if not adjusted by any factor (Column 1 Table 7).
The odd ratio between T2DM and HSV-2 adjusted for each of demographic and clinical
variables were also calculated (Column 2, Table 7). T2DM was 1.81 times more likely to
occur among individuals who were HSV-2 positive than among individuals who were not
if adjusted by gender (p = 0.0001); 1.52 adjusted by race (p = 0.0048); 1.65 (p = 0.0011)
adjusted by education; 1.63 (p = 0.0012) adjusted by smoking; 1.67 (p = 0.0003) adjusted
by blood pressure; 1.48 (p = 0.0150) adjusted by BMI; 1.64 (p = 0.0014) adjusted by
cholesterol level; 1.53 (p = 0.0054) adjusted by CRP; and 2.11 if adjusted by ferritin (p =
0.0008). Based on the confounding 10% rule (Vittinghoff, Glidden, Shiboski, &
McCulloch, 2012), it was observed that gender and ferritin were positive confounders,
while age, income and BMI were negative confounders of HSV-2.
To examine the predictive effects of multiple variables simultaneously, a stepwise
regression was performed (Columns 3 and 4, Table 7). After adjusting for all potential
predictive demographic variables for T2DM (age, gender, household income, BMI, CRP,
and ferritin), the association between T2DM and HSV-2 was no longer significant.
However, all confounding factors included in the regression model (Table 7) were
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significant at either alpha=0.10, 0.05, or 0.01. The presence of confounding implies that
the adjusted summary measure is a better estimate of the effect of the exposure on the
outcome of interest since it removes the effect of all possible confounders. Therefore,
model 4 (column 4, tables 7) provides the best effect estimate and confirms the null
results.

Table 7
Odds Ratios (95% Confidence Intervals) for T2DM Associated With HSV-2 by Selected
Characteristics Among U.S. 20 to 49 Years Old Population, NHANES, 1999-2010
Ref (negative)
HSV-2 (positive)
Age Group (35~49
vs 20~34)
Gender (Male vs
Female)
Race (nonWhite vs
White)
Education (high
school vs college or
higher)
Household Income
<$25,000
vs >$55,000
$25,000~54,999
vs >$55,000
Smoking (Smoker
vs nonsmoker)
Blood Pressure
(High vs Normal)
BMI
Overweight vs
Normal
Obesity vs Normal
Blood Cholesterol
Level
Borderline high vs
Desirable
High levels vs
Desirable
C reactive protein

(1) Crudea
1.00
1.66[1.23,2.23]***
3.91[2.85,5.36]***

(2) Adjustedb
1.00
1.66[1.23,2.23]***
1.33[0.97,1.83]*

(3) Adjustedc
1.00
1.02[0.67,1.53]
4.22[2.62,6.80]***

(4) Adjustedd
1.00
1.50[0.85,2.65]
3.03[1.61,5.71]***

1.38[1.02,1.88]**

1.81[1.36,2.41]***

1.43[0.93,2.22]

1.70[0.92,3.13]*

1.67[1.23,2.27]***

1.52[1.14,2.03]***

-

-

1.12[0.83,1.51]

1.65[1.23,2.21]***

-

-

1.88[1.06,3.35]**

2.48[1.36,4.54]***

2.12[0.91,4.93]*

2.01[1.16,3.47]**

2.37[1.32,4.24]***

2.29[0.98,5.38]*

1.24[0.81,1.88]

1.19[0.92,1.54]

1.63[1.22,2.19]***

-

-

3.14[2.15,4.59]***

1.67[1.27,2.20]***

-

-

-

2.45[1.09,5.52]**

-

6.91[2.56,18.7]***

1.10[0.77,1.55]

-

-

1.32[0.88,2.00]

-

-

1.48[1.08,2.03]**
2.30[1.44,3.66]***
7.53[4.70,12.1]***
1.64[1.22,2.21]***

1.53[1.14,2.07]***
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High or Average vs
Low or normal

3.39[2.37,4.84]***

-

2.22[1.16,4.27]**

Ferritin
2.11[1.38,3.24]***
Normal levels vs
1.70[1.01,2.86]**
2.10[0.84,5.23]
Low levels
High levels vs Low 4.89[2.55,9.38]***
4.42[1.52,12.8]***
levels
--: the predictor not included in the final multiple logistic regression model, * p < 0.10, ** p < 0.05,
***p < 0.01
a
: odds ratio (95% CI) btw T2DM by each risk factor only.
b
: odds ratio (95% CI) btw T2DM and HSV-2 adjusted by each risk factor.
c
: odds ratio (95% CI) btw T2DM and HSV-2 adjusted by demographic variables in one full model.
d
: odds ratio (95% CI) btw T2DM and HSV-2 adjusted by demographic and clinical variables in one full
model.

Similarly, the correlation between T2DM and the number of infections with HSV1+HSV-2 was also examined (Table 8). The results of this analysis were consistent with
those described in table 7. T2DM was associated with HSV-2, age, gender, race,
household income, blood pressure, BMI, and ferritin. Unadjusted rates indicate that
T2DM was 1.99 times more likely to occur among individuals who were seropositive for
both HSV-1and HSV-2 than among individuals who acquired neither one (p = 0.0042).
T2DM was 3.91 times more likely to occur among individuals aged 35~49 than among
individuals aged 20~34 (p < 0.0001); 1.38 times more likely to occur among male than
among female (p = 0.0392); 1.67 times more likely to occur among nonWhites than
among Whites (p = 0.0013); 1.88 times more likely to occur among individuals with a
household income below $25,000 than among individuals with a household income
between $25,000 and $49,999 (p = 0.0309); 2.01 times more likely to occur among
individuals with household income above $25,000 and less than $55,000 than among
individuals with household income above $55,000 (p = 0.0133); 3.14 times more likely to
occur among individuals with high blood pressure than among individuals with normal
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blood pressure (p < 0.0001); 2.30 times more likely to occur among overweight
individuals than among normal weight individuals (p = 0.0006) ; 7.53 times more likely
to occur among obese individuals than among normal weight (p < 0.0001); 3.39 times
more likely to occur among individuals with high to average level CRP than among
individuals with low to normal CRP (p < 0.0001); 1.70 times more likely to occur among
individuals with normal ferritin levels than among individuals with low levels
(p=0.0461); and 4.89 more likely to occur among individuals with high levels of ferritin
than among those with low levels (p < 0.0001) . However, T2DM was not associated
with HSV-1, education, smoking, and blood cholesterol level.
Adjusted rates determined that T2DM was 2.22 times more likely to occur among
individuals who were seropositive for HSV-1and HSV-2 than among individuals who
were not (p = 0.0004) adjusted by gender (Column 2, Table 8); 1.69 (p = 0.0355)
adjusted by race; 1.98 (p = 0.0042; adjusted by education; 1.96 (p = 0.0051) adjusted by
smoking; 2.09 (p = 0.0021) adjusted by blood pressure; 1.71 (p = 0.0287) adjusted by
BMI; 1.96 (p = 0.0057) adjusted by blood cholesterol; 1.82 (p = 0.0152) adjusted by
CRP; and 2.29 (p = 0.0246) if adjusted by ferritin. Having HSV-1and HSV-2 versus not
having acquired any herpes virus was not significantly associated with T2DM when
adjusted by age, gender, household income, BMI, CRP, or ferritin. However, all these
confounders exhibited significance in this model (Column 3 and 4, Table 8).
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Table 8
Odds Ratios (95% Confidence Intervals) for T2DM Associated With Herpes Simplex
Viruses (HSV-1and HSV-2) by Selected Covariates Among U.S. 20 to 49 Years Old
Population, NHANES, 1999-2010
(1) Crudea

(2) Adjustedb

(3) Adjustedc

(4) Adjustedd

1.20[0.78,1.85]

1.20[0.78,1.85]

1.02[0.57,1.83]

0.82[0.37,1.81]

1.99[1.25,3.18]***

1.99[1.25,3.18]***

1.10[0.56,2.16]

1.50[0.62,3.67]

3.91[2.85,5.36]***

1.02[0.66,1.59]

4.17[2.53,6.88]***

3.01[1.58,5.73]***

Gender (Male vs
Female)

1.38[1.02,1.88]**

1.42[0.88,2.32]
1.23[0.81,1.89]

1.44[0.94,2.20]*

1.69[0.94,3.03]*

Race (nonWhite
vs White)

1.67[1.23,2.27]***

2.22[1.44,3.43]***
1.10[0.70,1.71]

-

-

Education (high
school vs college
or higher)

1.12[0.83,1.51]

1.69[1.04,2.74]**
1.20[0.77,1.85]

-

-

Herpes Type
One type vs no
herpes (HSV-1)
Two types vs no
herpes (HSV-1
and HSV-2)
Age Group
(35~49 vs 20~34)

1.98[1.24,3.16]***
1.23[0.68,2.22]

Household
Income

1.56[0.77,3.15]
<$25,000
vs >$55,000
$25,000~54,999
vs >$55,000
Smoking
(Smoker vs
nonsmoker)

1.88[1.06,3.35]**

2.45[1.32,4.54]***

2.09[0.90,4.84]*

2.01[1.16,3.47]**

2.34[1.31,4.18]***

2.28[1.00,5.19]*

1.19[0.92,1.54]

1.20[0.78,1.84]

Blood Pressure
(High vs Normal)

3.14[2.15,4.59]***

1.96[1.23,3.12]***
1.34[0.85,2.10]

-

-

2.09[1.32,3.33]***
1.10[0.70,1.71]
1.71[1.06,2.77]**

BMI
Overweight vs
Normal
Obesity vs
Normal
Blood
Cholesterol Level

2.30[1.44,3.66]***

-

2.44[1.09,5.46]**

7.53[4.70,12.08]***

-

6.91[2.53,18.87]***

Borderline high
vs Desirable

1.10[0.77,1.55]

-

-

1.19[0.77,1.84]
1.96[1.22,3.15]***
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High levels vs
Desirable
C reactive protein

1.32[0.88,2.00]

High or Average
vs Low or
Normal
Ferritin

3.39[2.37,4.84]***

-

-

-

2.21[1.15,4.22]**

1.17[0.75,1.83]
[1.82,1.13 2.93]**

1.06[0.54,2.11]
2.29[1.11,4.70]**

Normal levels vs
1.70[1.01,2.86]**
2.10[0.85,5.22]
Low levels
High levels vs
4.89[2.55,9.38]***
4.52[1.54,13.25]***
Low levels
--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05,
***p<0.01
a
: odds ratio (95% CI) btw T2DM and each risk factor only.
b
: odds ratio (95% CI) btw T2DM and HSV adjusted by each risk factor.
c
: odds ratio (95% CI) btw T2DM and HSV, demographic variables, and smoke in one full model.
d
: odds ratio (95% CI) btw T2DM and HSV, demographic variables, smoke and all clinical variables in one
full model.

Relationship between CVD and HSV-2 and Burden of Infection
The interaction between CVD and HSV-2 and selected demographic and clinical
variables was also evaluated (Table 9). Similar to T2DM, results of the multiple logistic
analysis (Column 1, Table 9 & 10) indicated that CVD was associated with individuals
who were seropositive for HSV-2, age, education, household income, smoking, blood
pressure, BMI, CRP, and ferritin. Specifically, CVD was 2.19 times more likely to occur
among individuals who were HSV-2 positive than among individuals who did not (p =
0.0002) and 2.65 (Column 1, Table 10) times more likely to occur among individuals
who acquired both HSV-1and HSV-2 than among individuals who acquired neither one
(p = 0.0013); 4.81 times as likely to occur among individuals aged 35~49 than among
individuals aged 20~34 (p <0.0001); 1.62 times more likely to occur among individuals
with high school education than among individuals with college or higher education
(p = 0.0192); 2.24 times more likely to occur among individuals with household income

80
below $25,000 than among individuals with household income above $25,000 and less
than $55,000 (p = 0.0040); 1.73 times more likely to occur among individuals with
household income above $25,000 and less than $55,000 than among individuals with
household income above $55,000 (p = 0.0609); 3.66 times more likely to occur among
smoking individuals than among nonsmoking individuals (p < 0.0001); 2.43 times more
likely to occur among individuals with high blood pressure than among individuals with
normal blood pressure (p = 0.0017); 1.97 times more likely to occur among overweight
individuals than among normal weight individuals (p = 0.0185); 3.25 times more likely to
occur among obese individuals than among normal weight (p < 0.0001); 1.89 times more
likely to occur among individuals with high to average level CRP than among individuals
with low to normal CRP (p = 0.0130); 2.97 times more likely to occur among individuals
with high level ferritin than among individuals with low level ferritin (p = 0.0185).
Nonetheless, CVD was not associated with HSV-1, CMV, gender, race, cholesterol level,
or burden of infections.
The odds ratios between CVD and HSV-2 adjusted by each of the demographic
and clinical variables are shown (Column 2, Table 9 &10). CVD was found 1.73
(p=0.0097) times more likely to occur among individuals who were seropositive for
HSV-2 than among individuals who were not if adjusted by age (Column 2, Table 9);
2.21(p = 0.0001) adjusted by gender; 2.32 (p = 0.0001) adjusted by race; 2.13(p=0.0003)
adjusted by education; 1.91 (p = 0.0024) adjusted by smoking; 2.06 (p = 0.0011) adjusted
by blood pressure; 2.07 (p = 0.0009) adjusted by BMI; 2.16 (p = 0.0003) adjusted by
blood cholesterol; 2.12 (p = 0.0004) adjusted by CRP; and 2.07 (p = 0.0023) adjusted by
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ferritin. Based on the 10% rule (Vittinghoff et al., 2012), it was observed that age,
household income and smoking were negative confounders of HSV-2. To identify
potential confounders between CVD and HSV-2, a stepwise regression analysis was also
performed. CVD was not associated with HSV-2 when adjusted by age, household
income; and smoking and BMI (Column 3, Table 9).Nevertheless, all the confounding
variables were found significant at alpha=0.10, 0.05, or 0.01 (Column 4, Tables 9 & 10).
Table 9
Odds Ratios (95% Confidence Intervals) for CVD Associated With HSV-2 and Burden of
Infection by Selected Covariates Among U.S. 20 to 49 Years Old Population, NHANES,
1999-2010
HSV-2 (Yes vs No)
BURDEN*
1 vs 0
2 vs 0
3 vs 0
Age Group (35~49 vs 20~34)
Gender (Male vs Female)
Race (nonWhite vs White)
Education (high school vs college
or higher)
Household Income
<$25,000 vs >$55,000
$25,000~54,999 vs >$55,000
Smoking (Smoker vs nonsmoker)
Blood Pressure (High vs Normal)
BMI
Overweight vs Normal
Obesity vs Normal
CMVIGG
Blood Cholesterol Level
Borderline high vs Desirable
High levels vs Desirable
C reactive protein
High or Average vs Low or Normal
Ferritin
Normal vs Low
High vs Low

(1) Crudea

(2) Adjustedb

(3) Adjustedc

(4) Adjustedd

2.19[1.47,3.27]***

2.19[1.47,3.27]***
-

1.03[0.59,1.80]

1.08[0.59,1.95]
-

1.03[0.48,2.18]
0.69[0.28,1.68]
1.62[0.72,3.66]
4.81[3.04,7.63]***
0.89[0.60,1.31]
0.84[0.58,1.22]
1.62[1.08,2.42]**

1.73[1.15,2.62]***
2.21[1.50,3.25]***
2.32[1.53,3.52]***
2.13[1.42,3.18]***

5.19[2.59,10.37]***
-

4.48[2.25,8.94]***
-

1.50[0.88,2.55]
2.24[1.30,3.86]***
1.73[0.97,3.08]*
3.66[2.42,5.53]***
2.43[1.41,4.20]***
1.97[1.12,3.46]**
3.25[1.89,5.62]***
1.04[0.60,1.79]

1.91[1.26,2.87]***
2.06[1.35,3.16]**
2.07[1.36,3.15]***

2.16[1.44,3.24]***

1.07[0.69,1.66]
1.43[0.78,2.60]

2.45[1.39,4.32]***
1.92[1.06,3.48]**
2.47[1.39,4.41]***
-

2.34[1.33,4.10]***
1.80[0.94,3.42]*
2.44[1.40,4.27]***
-

-

3.18[1.45,6.97]***
3.67[1.70,7.93]***
-

-

-

-

-

-

-

2.12[1.41,3.18]***
1.89[1.12,3.20]**
2.07[1.30,3.27]**
1.36[0.61,3.04]
2.97[1.21,7.34]**

--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05,
***p<0.01 a: odds ratio (95% CI) btw CVD by each risk factor only.
b
: odds ratio (95% CI) btw CVD and HSV-2 adjusted by each risk factor.
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c: odds ratio (95% CI) btw CVD and HSV-2, demographic variables in one full model.
d: odds ratio (95% CI) btw CVD and HSV-2, demographic variables, and clinical and biometric variables
in one full model.
*: number of herpes infections (HSV-1 or HSV-2, HSV-1 and HSV-2, and HSV-1 and HSV-2 and (CMV)

Table 10 illustrates the odd ratio for CVD and HSV-1 and HSV-2 and selected
markers. Study results indicated that CVD was 1.84 times more likely to occur among
individuals who were seropositive to both, HSV-1 and HSV-2 than among individuals
who were not (p = 0.0524) if adjusted by age; 2.66 (p = 0.0006) adjusted by gender;
3.02 (p=0.0008) adjusted by race; 2.40 (p = 0.0051) adjusted by education; 2.20
(p = 0.0094) adjusted by smoking; 2.72 (p = 0.0012) adjusted by blood pressure; 2.45
(p =0.0062) adjusted by BMI; 2.60 (p = 0.0015) adjusted by blood cholesterol level; 2.54
(p = 0.0020) adjusted by CRP; 2.63 (p = 0.0056) adjusted by ferritin. The predictive
effects of multiple variables were also assessed with a stepwise regression (3rd and 4th
columns, Table 10). Results were comparable with T2DM, indicating not significant
association between CVD and having HSV-1 and HSV-2 if adjusted by age, household
income and smoking; however, age, household income and smoking showed significance
in all regression models.
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Table 10
Odds Ratios (95% Confidence Intervals) for CVD Associated With HSV-1 and HSV-2 and
Selected Markers Among U.S. 20 to 49 Years Old Population, NHANES, 1999-2010
(HSV)
(1) Crudea

(2) Adjustedb

(3) Adjustedc

(4) Adjustedd

Herpes Type
One types vs No herpes (HSV-1)
Two types vs No herpes (HSV-1 +
HSV-2)

1.35[0.81,2.24]
2.65[1.48,4.73]***

1.35[0.81,2.24]
2.65[1.48,4.73]***

0.67[0.35,1.30]
0.79[0.35,1.77]

0.75[0.38,1.47]
0.87[0.36,2.13]

Age Group (35~49 vs 20~34)

4.81[3.04,7.63]***

1.12[0.66,1.90]
1.84[0.99,3.39]*

5.51[2.61,11.65]***

4.68[2.25,9.71]***

Gender (Male vs Female)

0.89[0.60,1.31]

1.35[0.82,2.23]
2.66[1.53,4.60]***

-

-

Race (nonWhite vs White)

0.84[0.58,1.22]

1.44[0.86,2.42]
3.02[1.61,5.68]***

-

-

Education (high school vs college
or higher)

1.62[1.08,2.42]**

1.27[0.75,2.15]

-

-

2.53[1.47,4.36]***
1.97[1.10,3.54]**

2.39[1.37,4.18]***
1.83[0.97,3.46]*

2.52[1.42,4.49]***

2.47[1.42,4.31]***

2.40[1.31,4.41]***
Household Income

0.93[0.52,1.66]
1.50[0.74,3.04]

<$25,000 vs >$55,000
$25,000~54,999 vs >$55,000

2.24[1.30,3.86]***
1.73[0.97,3.08]*

Smoking (Smoker vs Nonsmoker)

3.66[2.42,5.53]***

Blood Pressure (High vs Normal)

2.43[1.41,4.20]***

BMI
Overweight vs Normal
Obesity vs Normal

-

-

-

3.17[1.44,6.95]***
3.68[1.72,7.91]***

-

-

1.38[0.81,2.34]
2.45[1.30,4.62]***
1.97[1.12,3.46]**
3.25[1.89,5.62]***

Blood Cholesterol Level
Borderline high vs Desirable
High levels vs Desirable

1.25[0.75,2.09]
2.20[1.22,3.96]***
1.16[0.69,1.97]
2.72[1.50,4.95]***

1.34[0.80,2.22]
2.60[1.45,4.64]***
1.07[0.69,1.66]
1.43[0.78,2.60]
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C reactive protein
High or Average vs Low or Normal

1.33[0.80,2.21]
2.54[1.42,4.56]***
1.89[1.12,3.20]**

Ferritin

-

-

-

-

1.24[0.63,2.43]
2.63[1.34,5.18]***

Normal levels vs Low levels
High levels vs Low levels

1.36[0.61,3.04]
2.97[1.21,7.34]**

--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05, ***p < 0.01
a: odds ratio (95% CI) btw CVD and each risk factor only.
b: odds ratio (95% CI) btw CVD and HSV adjusted by each risk factor.
c: odds ratio (95% CI) btw CVD and HSV, demographic variables, and smoke in one full model.
d: odds ratio (95% CI) btw CVD and HSV, demographic variables, smoke and all clinical variables in one full model.

Summary
The multivariate regression analyses accounting for sampling design effects and
sampling weight indicated that both T2DM and CVD were significantly associated with
HSV-2, but not associated with HSV-1, CMV or burden (multiple infections). Results
indicated that T2DM and CVD were associated with demographic variables age,
household income, blood pressure, BMI, CRP and ferritin; however, only T2DM was
associated with gender and race while CVD was associated with education and smoking.
Surprisingly, neither T2DM nor CVD was associated with blood cholesterol. Further
examination revealed that nonwhite men, aged 35-49, with household income ≤$55,000,
with high blood pressure, overweight or obese, with average to high level of CRP, or high
ferritin levels were more likely to increase the risk for developing T2DM. Similarly,
older individuals aged 35-49, smoking individuals, or those individuals with a high
school education background, a household income ≤$25,000 or between $25,000 and
≤$55,000, high blood pressure, overweight or obese, with an average or high CRP level,
or high ferritin levels were more likely to increase the risk for developing CVD.
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Further examination revealed that gender, age, household income, BMI and
ferritin were confounders of the association between T2DM and HSV-2 while age,
household income and smoking were cofounders of the association between CVD and
HSV-2. Based on the stepwise regression model, the final regression model for
describing the relationship between T2DM and HSV-2 was determined after adjusting for
the demographic and clinical variables, age, gender, household income, BMI, CRP and
ferritin. No association between T2DM and HSV-2 was observed after factoring for all
confounding variables. Similarly, no significant association was observed between CVD
and HSV-2 after adjusting for age, household income, and BMI. A similar trend was
observed between T2DM and CVD and seropositivity to both, HSV-1 and HSV-2. After
controlling for all confounding factors, no significant association was observed between
HSV-2 and T2DM or CVD and having both HSV-1and HSV-2. However, a significant
association was observed between T2DM and CVD and high CRP and ferritin levels
across all analyses. Discussion on these findings and their implication on social changed
are further discussed in Chapter 5.
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Chapter 5
Discussion, Conclusion, and Implications for Social Change
Introduction
The global prevalence and incidence of HSV is of great public health significance
(CDC, 2010; Smith & Robinson, 2002; Wald & Corey, 2007; Xu et al., 2006). The ability
of HSV to readily adapt to its host (human or animal), reactivate during the lifetime of
the host, and induce recurrent autoimmune and inflammatory responses is believed to
increase an individual’s susceptibility to disease (Kampoli et al., 2011; Lloyd-Jones et al.,
2010; Lutsey et al., 2009; Pickup, 2004; van der Kleij et al., 2003). Despite the body of
evidence implicating herpes and other viral and bacterial infections in the pathogenesis of
T2DM and CVD, most studies have generated inconsistent results (Lutsey et al., 2009;
Rupprecht et al., 2001; Sun et al., 2004) and this study is no exception. Outcomes from
this study indicated no association and therefore do not support the hypothesis that HSV
or multiple infections with HSV and CMV increase the risk of developing either T2DM
or CVD. In contrast, findings from this study support the premise that pathogenic
inflammation may be a secondary phenomenon and not directly associated with the
disease (ASM, 2014).
Discussion
This study was based on the premise that infectious agents can increase chronic
inflammation—a risk factor for several common chronic diseases, including T2DM and
CVD. The relationship between human pathogenic HSVs and T2DM or CVD was
examined to determine whether an association exists or if it is merely a secondary effect.
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Based on data availability, the effect of two inflammatory markers, ferritin and CRP, on
T2DM and CVD was studied. Established risk factors for both, T2DM and CVD,
including hypertension, overweight or obese, and smoking status were also examined in
the present study. Data collected by NHANES from 1999-2010 on individuals between
the ages 20-49 was used to conduct this study.
According to national trends, the risk of developing T2DM increases with age; is
greater among Hispanics, African Americans, Native Americans and Asians; is greater
among individuals who are obese or overweight, and have hypertension. (ADA, 2014;
CDC, 2014; Geiss et al., 2014; Menke, Rust, Fradkin, Cheng, & Cowie, 2014; Paeratakul,
Lovejoy, Ryan, & Bray, 2002). The prevalence of T2DM in this sample was consistent
with the overall national trends by gender, age, race/ethnicity, hypertension, and body
mass index. A significantly higher prevalence of T2DM was observed among males than
females, which supports the new trend in gender distribution of T2DM due to differences
in body fat, insulin resistance, sex hormones, and blood glucose levels (Faerch, BorchJohnsen, Vaag, Jorgensen, & Witte, 2010; Geer & Shen, 2009; Logue et al., 2011;
Perreault et al., 2008; Sicree et al., 2008). Further, this study found no relation between
smoking and T2DM, which is surprising given the fact that smoking is a well-established
risk factor for T2DM. Nonetheless, a possible explanation for this finding is the decline
of cigarette smoking among adults in the last decade, particularly among individual with
diabetes (Fan et al., 2013).
T2DM is known to increase the risk of CVD and similar risk factors have been
associated with both diseases (Grundy, Pasternak, Greenland, Smith, & Fuster, 1999;
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Laakso, 2008; Luscher et al., 2003). Consequently, similar results in the prevalence of
CVD were expected. The prevalence of CVD in this sample was also consistent with U.S.
trends by age, high blood pressure, smoking, and BMI, but not by gender or ethnicity
(Hahn, Health, & Chang, 1998). Surprisingly, neither T2DM nor CVD was related to
high cholesterol. It is possible that this study may have been limited to detect significant
prevalence differences in cholesterol levels among study participants due to sample size,
in addition to the multidimensional factors associated with T2DM and CVD (Dokken,
2008; Kalofoutis et al, 2007).
The prevalence of high CRP and ferritin levels in this study was also consistent
with national estimates (Khera et al, 2005; Woloshin, & Schwartz, 2005). High CRP
levels were observed among females, nonHispanic Blacks and Hispanics. Significantly
higher CRP levels were, however, observed among nonHispanic Whites. It is possible
that the analysis performed to assess race/ethnicity in this study may have been biased
given that the majority of the study participants were nonHispanic Whites. Additionally,
race and/or ethnicity in NHANES data is restricted to only a few classifications,
including nonHispanic White, nonHispanic Black, Hispanics, and other racial groups,
which limit the subgroup analyses in this study. Further, this study also found, although
slightly, higher CRP levels among individuals aged 20-34 than in the older group. These
unexpected and divergent results may be an indication of a new trend in the distribution
of CRP in the U.S. since CVD has been risen among young people due to childhood
obesity and diabetes (Freedman, Zuguo, Srinivasan, Berenson, & Dietz, 2007). Based on
Freedman and associates (2007) findings, approximately 70% of obese youth between the
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ages of 5-17 had at least one risk factor for CVD, including prediabetes and high blood
pressure.
Contrary to CRP, the prevalence of ferritin levels in this sample population was
predominantly higher among males, nonHispanic Whites, and study participants aged 3549. Except for the factor race which limitations were previously discussed, these findings
align with the overall distribution of serum ferritin reported by WHO (2014). Further
analyses indicated that the prevalence of T2DM and CVD (age-adjusted) was
significantly higher among individuals with the average to high CRP and high ferritin
levels. These results support the use of CRP and ferritin levels as markers of chronic
inflammatory disease and potential independent predictors of T2DM and CVD (Foroubi
et al., 2007; Halcox et al., 2014; Watson et al., 2012). Whereas gender differences were
observed with serum ferritin in this study, these results provide value to the use of serum
ferritin in assessing the risk for T2DM and CVD.
A decrease in the prevalence of HSV-1, HSV-2, and CMV over the last decade
was observed in this study population, which also shows consistency with the national
estimates (CDC, 2010a, 2010b; Smith et al., 2002; Staras et al., 2006; Xu et al., 2006). A
similar tendency was observed among participants who had two or three herpes virus
infection indicating a possible additive effect, particularly between HSV-1 and HSV-2,
since the incidence of genital herpes with HSV-2 has been decreasing while potentially
increasing with HSV-1 (Malkin, 2004). All three herpes virus infections were higher
among females and individuals aged 35-49; however, the prevalence rates for HSV-2
were twice as high. Significant racial differences were observed in the prevalence of
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HSV-2 among nonHispanic Blacks whereas higher prevalence rates of HSV-1 were
observed among Hispanics, followed by other racial populations and nonHispanic Blacks
as documented in prior studies (Fanfair et al., 2013; Halford et al., 2004; Kriebs, 2008).
Overall, results from unadjusted and adjusted analyses determined an association
between T2DM and HSV-2 OR = 1.66 [1.23, 2.23], T2DM and both HSV-1 and HSV-2
OR = 1.99 [1.25, 3.18], CVD and HSV-2 OR = 2.19 [1.47, 3.27] and CVD and both
HSV-1 and HSV-2 OR = 2.65 65[1.48, 4.73]. Nevertheless, after controlling for all
potential confounding variables in one full model, including smoking status, blood
pressure, BMI, CRP, and serum ferritin, the associations were no longer significant.
There was also no association between T2DM or CVD and HSV-1, CMV and burden of
infection ≥1. These results support preceding evidence that no association exists between
HSV and CMV and T2DM or CVD. However, all the covariates included in the final
regression analyses showed a significant association with T2DM and CVD. These
findings are consistent with the existing evidence that established risk factors such as
hypertension, overweight or obese, and smoking status are associated with T2DM and
CVD.
Similar differing results have been reported in preceding studies investigating the
association of multiple pathogens with chronic diseases. Lutsey and colleagues (2009)
reported a high prevalence of diabetes among individuals with CMV OR = 1.73 [1.06,
2.84], HSV-1 and HSV-2 OR = 2.73 [1.30, 5.75] and with more than 3 pathogens OR =
1.68 [1.07, 2.64]; however, these associations were no longer significant after adjusting
for selected demographic variables CMV OR = 1.02 [0.60, 1.72], HSV-1 and HSV-2
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OR = 1.50 [0.68, 3.28], and ≥ 3 pathogens OR = 0.81 [0.48, 1.37]. Null results were also
documented by Mendy and colleagues (2013) who conducted a study with the same
NHANES data (1999-2010) and age group 20-49 to investigate the relationship between
CVD and HSVs. No association was found between CVD and HSV-1 OR = 1.13 [95%
CI = 0.79-1.62]. Whereas a positive association between HSV-2 and premature CVD
OR = 1.56 [95% CI = 1.09-2.21] was reported in this study, this association could be
debated as a weak association and may need further examination (Rosenthal, 1996).
Other preceding work investigating the link between pathogens, socioeconomic position
(SEP) and CVD reported no association between CVD and HSV-1, CVD and both HSV1 and HSV-2, or CVD and CMV after adjusting for SEP (Simanek, Dowd, & Aiello,
2009). In contrast, CMV was identified as a possible mediator between socioeconomic
and CVD and a co-factor in atherosclerosis (Simanek et al, 2009).
Despite the null findings, the present study provides additional support to the
existing literature that there is no association between T2DM or CVD and the studied
herpes virus infections. It is possible, however, that these infectious agents are possible
mediators in the inflammation process and co-factors in the early stage of the disease as
reported in previous work (Bassols et al., 2009; Vlassara et al, 2002; Watts et al., 2008).
Further, the null results of this study may be related to the study and analysis design.
Although this study used a large sample size, subanalyses lowered the numbers and may
have biased results. Further, a stepwise regression analysis was utilized since it allows for
predictive variables to be added sequentially and altogether in a full model. A few
controversial points, however, have been made with regards to stepwise regression,
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including tests bias, type I error, distribution of F-statistic and over-simplifications of
final models (Copas, 1983; Hurvich, & Tsai, 1990; Roecker, 1991; Wilkinson, & Dallal,
1981). Nevertheless, all predictive variables in this study were manually selected;
therefore, the issues mentioned above should not have influenced the results. Other
potential factors that could have affected the results are variable manipulations in the
analyses. The variable race/ethnicity, for instance, was recategorized from a multiple
levels variable to a binary variable due to analysis constrains. Yet, given that most of this
study population were nonHispanic Whites, aggregating all the underestimated
populations should have in fact canceled out any effects. Additionally, this study looked
at the distribution of all three herpes viruses (HSV-1, HSV-2 and CMV) by selected
demographic variables, but not across all studied independent variables and covariates. It
may be possible that the results may have been affected by some variable distribution;
yet, the focus of the study was on two dependent variables, T2DM and CVD, and main
covariates indicated normal distribution. Furthermore, the cutoff points for measuring
certain biochemical parameters used in this study may have been different from those
used in previous studies, which may have caused the differing results.
Nevertheless, based on the evidence of this study, which associations were
contributed to confounding, it is presumed that potential confounding factors for T2DM
and CVD, other than demographic factors, were not adequately controlled in some of the
previous studies. It is also assumed that other factors such as differences in settings,
location, and study design may be related to the discrepancy between this study’s results
and those preceding. Some of the limitations documented in prior works investigating the
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role of infection in the prevalence of T2DM and CVD includes clinical populations,
age/race-specific, and small sample sizes, which may preclude general population
inferences (Lutsey et al., 2009; Paeratakul et al., 2002; Roberts et al., 2005a, 2005b; Sun
et al., 2004). When compared to other cross-sectional studies, the present study does
align for the most part with reported results (Lutsey et al., 2009; Mendy et al, 2013).
Whereas causal factor cannot be assumed with the study design, and results were null,
this study raises important questions to be addressed in future research.
Limitations
This study used multiple years of NHANES data which requires different weights
for analysis and is particularly important for variance estimation. This, however, resulted
in a significant increase in the number of missing and a decrease in sample size across
most of the studied variables. Further, the fact that CRP and ferritin levels are potentially
linked to both diseases made it difficult to determine their true utility for each disease in
this study. Additionally, data for these and other inflammatory markers were not
consistently collected by NHANES throughout the 12 years of data collection period,
making it difficult to make unbiased comparison analysis and inferences.
Implications for Social Change
Despite the null results, this study provides the medical community and the public
health field with valuable information that can be translated into clinical practice.
Although there is no definitive evidence that lowering CRP or serum ferritin levels can
reduce the risk for diabetes or CVD, it has been documented that managing and
controlling traditional risk factors, such as blood pressure, nutrition, exercise, and
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smoking, often lead to lowering these inflammatory markers (Ridker, 2000; Ziegler,
2005). Existing guidelines could be expanded for primary and secondary prevention of
CVD and T2DM using CRP as a prognostic tool for CVD (Ballantyne et al., 2005; Blake
et al., 2002; Davison et al., 2011; Khera et al., 2005; Ridker, 2000) and serum ferritin as a
marker for T2DM and CVD even in healthy individuals (Forouhi et al, 2007; Olesnevich
et al., 2012; Ossewaarde, 1998; Ponikowska et al., 2013). Although CPR testing for CVD
risk assessment continues to be a subject of debate (Capuzzi & Freeman, 2007), using
CRP as a marker for inflammatory disease is a widely accepted means for assessing
metabolic syndrome risk and diabetes (Ballantyne et al., 2005; Blake et al., 2002; Ridker,
2000). CPR has also been used to investigate the role of pathogen burden in relation to
increased risk for atherosclerosis (Zhu et al., 1999).
Implications for Future Research
Findings from this study expand on the existing evidence that no association
exists between herpes viruses (HSV-1, HSV-2, and CMV) and T2DM and CVD. The
high prevalence of HSV-2 observed among individuals with T2DM and CVD, however,
does raise the question whether infections agents have an etiologic role in disease
development or if having a chronic disease increases the susceptibility to infection.
Conflicting results underscore the need for more collaborative research across diseases
like T2DM, CVD and HSV which are traditionally housed in separate silos for research
and funding. Although no association was found in this study; certainly, conflicting
growing evidence investigating the relation between infectious agents, particularly
lifelong viruses, and chronic inflammatory diseases calls for causality research.
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Longitudinal studies are particularly useful in detecting changes in a population over
time, and the best method for thoroughly explore whether an association really exists
between pathogens and chronic diseases or if it is merely an epiphenomenon.
Understanding this relationship is imperative for developing preventive measures and
treatment for T2DM and CVD. Further, the effect of the studied inflammatory markers
(CRP and serum ferritin) as potential predictors for T2DM and CVD and mediators in the
activation of inflammation still is unclear (Laakso, 2008; Vlassara et al., 2002; Watson et
al., 2012; Watts et al., 2008). Further investigation is needed to advance understanding of
the interrelationship between pathogenic agents, inflammation and chronic diseases. Last,
high-risk groups often predisposed to chronic disease-related complications and
susceptible to infections should be closed examined in future studies.
Conclusion
This study is the first to investigate the association between HSV and two
multifactorial chronic diseases for which the primary etiology is unknown, T2DM and
CVD. The present work also examined the relationship between two inflammatory
markers (CRP and serum ferritin) and T2DM and CVD. Twelve years of cross-sectional
data were used to generate a representative and acceptable sample size for this study.
Results from this national representative sample indicated that being infected with HSVs,
CMV, or with two or three herpes viruses does not increase the risk for developing
T2DM or CVD. These findings suggest that infection may be a secondary phenomenon
and is not directly associated with disease. However, considering the well-established
connection between infection-induced autoimmune inflammatory response and disease, it
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is presumed that perhaps pathogens may function as mediators or co-factors in the
inflammatory response process, but not directly involved in the etiology of the disease.
While causal studies may provide more precise information and better opportunities to
assess, diagnose, and treat T2DM and CVD, the complexity of these two top leading
causes of death in U.S. leads to the question if developing and implementing more
effective prevention measures would be the best approach to address these two common
chronic diseases.
Despite this study’s marginal findings on infection and chronic disease, additional
results from this study showed an association between inflammatory markers and T2DM
and CVD. These results suggest that individuals with high levels of CRP or serum ferritin
may be at higher risk of developing T2DM or CVD; these findings are of great
significance mainly because the potential role that inflammatory markers may play in
chronic inflammation and disease. Inflammatory markers and other biomarkers have been
used for generations by scientists as disease status indicators; however, their reliability
and validity as predictive tools for inflammatory diseases are still in debate. Whereas
sensitivity and specificity measurements of biomarkers may be needed for determining
progression and severity of a disease, the application of biomarkers should be included in
routine screening tests to assist in disease prediction, diagnosis, management, and
treatment.
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